Functional analysis of human IL-35 in immune regulation by Zeiner, Sabrina
1 
 
 
 
DIPLOMARBEIT 
 
Titel der Diplomarbeit 
 
Functional analysis of human IL-35 in immune regulation 
 
angestrebter akademischer Grad 
Magistra der Naturwissenschaften (Mag. rer.nat.)  
 
 
 
Verfasserin / Verfasser: Sabrina Zeiner 
Matrikel-Nummer: 0304180 
Studienrichtung:  Genetik-Mikrobiologie A441 
Betreuer: Ao. Univ.Prof.Dr. Johannes Stöckl 
Univ.Prof.Dr. Thomas Decker 
 
 
 
Wien, im April 2010  
 
2 
 
 
 
 
 
 
 
 
Meinen Eltern gewidmet 
 
 
 
 
 
 
 
 
 
 
3 
 
Acknowledgement 
Zu allererst möchte ich Prof. Dr. Johannes Stöckl danken, der mir 
ermöglichte in seiner Gruppe zu arbeiten und mir stets mit hilfreichen 
Anregungen und Antworten zur Seite stand, die es mir erlaubten meine 
Arbeit erfolgreich abzuschließen. 
Mein Dank gilt auch Mag. Maria Seyerl, die mir als Betreuerin vieles 
beigebracht hat und immer einen guten Rat für mich parat hatte. 
Weiters danke ich Dr. Otto Majdic, der mich mit Antikörpern versorgte, die 
ich für meine Arbeit dringend brauchte. 
Auch danken möchte ich Petra Cejka, die mir die Antikörper zukommen 
ließ und stets ein offenes Ohr hatte, sowie Claus Wenhardt, der mir viel 
Arbeit abgenommen hat, da er meine Proben maß. Weiters Stefan Hopf, 
der immer ein guter Gesprächspartner war und allen anderen Kollegen 
und Kolleginnen. 
Mein besonderer Dank gilt meinen Eltern, Susanne und Thomas Zeiner, 
die mir das Studium ermöglichten und mir in jeder Sekunde zur Seite 
standen. Außerdem danke ich meinen beiden Schwestern Cornelia und 
Marcella, die mich immer unterstützt haben.  Besonderer Dank gilt auch 
meinem Freund Arno, der stets an mich geglaubt hat und ein liebevoller 
Begleiter war. 
Außerdem danke ich Marion für ihre unermüdliche 
Diskussionsbereitschaft. 
  
4 
 
Abstract 
Interleukin-35 (IL-35) is a novel member of the IL-12 family and consists of 
the subunits Epstein Barr virus induced gene 3 (EBI3) and p35, which it 
shares with IL-27 and IL-12, respectively. The classical IL-12 family 
members (IL-12, IL-23, IL-27) are produced by antigen presenting cells, in 
particular dendritic cells (DCs), and regulate T cell function. Here we 
demonstrate that human IL-35, produced by IL-35+ regulatory T cells, is an 
inhibitory factor for DCs but not T cells. Induction of proliferation of T cells 
with allogeneic DCs was reduced when we added graded amounts of 
recombinant IL-35. This effect could be observed with immature DCs as 
well as with LPS-stimulated DCs. In contrast, IL-35 did not diminish the 
proliferation of purified peripheral blood T cells as well as naïve T cells 
isolated from cord blood upon activation with anti-CD3, CD3/CD28 or 
CD3/CD63 mAbs. We further demonstrate an inhibitory effect of IL-35 on 
the proliferation of the epithelial HeLa Ohio cell line, but not on other cell 
lines. Moreover, pretreatment of DCs with IL-35 inhibited their T cell 
stimulatory capacity as well. The cytokine profile of these cells activated 
with LPS illustrates a diminished IL-10 and IL-12p40 release and a slight 
increase in IL-6, IL-1β and TNFα secretion in comparison to untreated 
DCs. The surface marker profile of DCs remains unaffected after IL-35 
treatment. We exhibit that an IL-35 fusionprotein binds to DCs and HeLa 
Ohio cells but not to peripheral T cells and all other tested cell lines.  The 
expression of the subunits of IL-35 (EBI3 and p35) is up-regulated in T 
cells stimulated with human rhinovirus treated DCs (R-DCs) and in T cells 
stimulated with DCs which were activated with IFNα. The CD2 expression 
level on T cells co-cultured with R-DCs is lower than on T cells cultivated 
with DCs. We found out that about 1.6% of total T cells in the peripheral 
blood are CD2-/low. Thus, IL-35 differs from the other members of the IL-12 
family in cause of acting on DCs and not on T cells. 
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Zusammenfassung 
Interleukin-35 (IL-35) ist ein neues Mitglied der IL-12 Familie und besteht 
aus den Untereinheiten Epstein Barr virus induced gene 3 (EBI3) und p35. 
EBI3 ist außerdem ein Bestandteil von IL-27 und p35 fungiert in dem 
Zytokin IL-12 als Untereinheit. Die klassischen Mitglieder der IL-12 Familie  
(IL-12, IL-23, IL-27) werden von Antigen präsentierenden Zellen, wie zum 
Beispiel dendritische Zellen (DCs), produziert und regulieren T Zell 
Funktionen. Hier identifizieren wir das von IL-35+ regulatorischen T Zellen 
produzierte humane IL-35 als inhibitorischen Faktor für DCs jedoch nicht 
für T Zellen. Die Induktion der T Zell – Proliferation eingeleitet durch 
allogene DCs war reduziert als verschiedene Mengen des rekombinanten 
IL-35 hinzugefügt wurden. Dieser Effekt wurde mit unreifen DCs genauso 
wie mit LPS – stimulierten DCs erreicht. Nach einer Aktivierung von T- 
Zellen mittels Antikörpern gegen CD3, CD3/CD28 oder CD3/CD63 konnte 
die Proliferation von gereinigten peripheren Blut-T Zellen sowie von naiven 
T Zellen des Nabelschnurbluts durch IL-35 nicht gehemmt werden. 
Weiters zeigen wir einen hemmenden Effekt von IL-35 auf die Proliferation 
der HeLa Ohio Zelllinie, epitheliale Zellen aus einem humanen zervikalen 
Karzinom. Eine vorangehende Behandlung von DCs mit IL-35 (IL-35-DCs 
genannt) führte auch zu einer inhibierten Kapazität T Zellen zu stimulieren. 
Das Zytokin-Profil jener IL-35-DCs, die mit LPS aktiviert wurden, zeigt eine 
verringerte IL-10 und IL-12p40 Produktion und einen leichten Anstieg in 
der IL-6, IL-1β und der TNFα Sekretion im Vergleich zu unbehandelten 
DCs. Das Oberflächen-Marker-Profil der DCs weist keine Veränderung 
nach der IL-35 Behandlung auf. Wir konnten außerdem feststellen, dass 
ein IL-35 Fusionsprotein an DCs und HeLa Ohio Zellen bindet jedoch nicht 
an periphere T Zellen und alle anderen getesteten Zelllinien. IL-35 wird 
von regulatorischen T Zellen, die mit humanen Rhinovirus aktivierten DCs 
ko-kultiviert wurden, produziert. Hier demonstrieren wir eine 
Hochregulierung der beiden IL-35 Untereinheiten, EBI3 und p35, in T 
Zellen nach einer R-DCs Stimulierung. Auch T Zellen, die mit IFNα 
aktivierten DCs stimuliert wurden, zeigen eine Steigerung der EBI3 und 
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p35 Expression. Wir konnten eine Verringerung der CD2 Expression auf 
jenen T Zellen feststellen, die mit R-DCs kultiviert wurden. Es wird eine 
CD2low/-/CD3+  T Zell Population in mononukleären Zellen von frischem 
Blut gezeigt, die zu circa 1,6% der T Zellen in verschiedenen Spendern 
vorkommt. Zusammenfassend unterscheidet sich IL-35 von den anderen 
Mitgliedern der IL-12 Familie, weil es auf DCs aber nicht auf T Zellen wirkt.  
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Abbreviations 
APC antigen presenting cell 
ATCC American type culture collection 
BSA bovine serum albumin 
CCR chemokine receptor 
CD cluster of differentiation 
cpm counts per minute 
CTL  cytotoxic T lymphocyte 
CTLA-4 cytotoxic T lymphocyte antigen 4  
DC dendritic cell 
DMSO Dimethylsulfoxide 
EBI3 Epstein Barr virus induced gene 3 
ER endoplasmic reticulum 
FASL FAS ligand 
FITC fluorescin-5-isothiocyanate 
G-CSF granulocyte-colony stimulating factor  
GM-CSF granulocyte-macrophage colony stimulating factor 
HRV human rhinovirus 
IFN interferon 
Ig immunoglobulin  
ICAM-1 intercellular adhesion molecule 1  
IL interleukin 
iNKT invariant natural killer T cell 
JAK-STAT Janus activated kinase–signal transducer and activator of transcription 
kDa kilo Dalton 
LC Langerhans cell 
LPS lipopolysaccharide 
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mAb monoclonal antibody 
MACS magnetic activated cell sorting 
MFI mean fluorescence intensity 
MHC major histocompatbility complex 
MLR mixed leucocyte reaction 
MV mean value 
MNC mononuclear cells 
moDCs monocyte derived dendritic cells 
MyD88 myeloid differentiation factor 88  
NK natural killer cells 
OG oregon green 
PBMNC peripheral blood mononuclear cells 
PE phycoerythin  
PBS phosphate buffered saline 
R-DC human rhinovirus activated dendritic cells 
SD standard deviation 
TAP transporters associated with antigen processing 
TCID tissue culture infectious dosis 
TCR T cell receptor 
TGF transforming growth factor 
TH T helper cell 
TLR toll-like receptor 
TNF tumor necrosis factor 
T regs  regulatory T cells 
ZYM Zymosan 
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1 INTRODUCTION 
1.1   Cytokines 
The name cytokine derived from Greek and means “to set cells in motion“. 
Cytokines are 8 to 30 kDa intracellular signalling peptides acting either in 
an autocrine, paracrine or endocrine way (1). They are secreted by cells of 
the innate and adaptive immune system in response to diverse antigens or 
as response to former distributed cytokines. The cytokines bind to 
receptors on target cells which activate intracellular signalling pathways 
(2).  
Cytokines are divided into two related groups, the type I and the type II 
hematopoietic cytokine/receptor families, and an IL-1/Toll-like family group 
(3). The type I cytokine family consists of 34 human cytokine receptor 
chains and 27 ligands. These cytokines, mostly interleukins (IL), function 
as immunomodulators and share several structural motifs (3,4). The 
receptors of this family share an extracellular fibronectin-like domain with 4 
cysteines in the membrane-distal region and a membrane-proximal 
WSXWS motif (5). Most of these cytokines are monomers with a 
conserved 4-fold α-helical core structure (4,6).  
The type II cytokine family differs from the type I cytokine family in 4 
cysteine residues in the membrane-proximal region and lacks the WSXWS 
motif in the receptors (7,8). Distinct subunits of the receptors can 
heterodimerize and form complexes (8). This family includes interferons 
and some related cytokines such as IL-10 and IL-19 (9). 
The third group of cytokines, the IL-1/Toll-like family includes only two 
interleukins, IL-1 and IL-18, and the Toll-like receptors (TLRs) (10).  
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1.2   Interleukin-12 (IL-12) family  
The IL-12 cytokine family, which is also linked to the IL-6 cytokine 
superfamily, consists of IL-12, IL-23 and IL-27 and the recently described 
IL-35 (11). The members are heterodimeric cytokines that share ligand 
and receptor subunits, and are important actors in innate and adaptive 
immunity (12). IL-12 was first described in 1989 (13) as the first type I 
cytokine having a heterodimeric structure. They are composed of an α 
subunit with helical structure and a β subunit. IL-12 family members often 
share one of the subunits (3). All of these cytokines exhibit a response to 
microbial and host immune stimuli and have immunomodulatory functions 
on T cells promoting their expansion and differentiation and inducing 
interferon-γ (IFNγ) production (14,15). Signal transduction occurs via 
Janus activated kinase–signal transducer and activator of transcription 
(JAK-STAT) pathways (14).  
 
Figure 1: IL-12 cytokine family (Collison and Vignali, 2008, Immunol Rev, 226:248-
62) 
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1.3   The classical IL-12 family members 
 
Interleukin-12 (IL-12) 
IL-12 comprises the subunits p35 (α) and p40 (β) (16). The p40 subunit 
shows similarities to cytokine receptors and the p35 subunit is related to 
IL-6 and Granulocyte-Colony Stimulating Factor (G-CSF). The expression 
level of p40 is higher than needed for the heterodimer formation of 
p40/p35 (17,18). IL-12 is induced in a T cell independent way by microbial 
products via TLRs and in a T cell dependent manner through CD40-
CD40L interaction (15). It is produced by monocytes, macrophages, 
dendritic cells, neutrophils and B cells. Inhibition of IL-12 production 
occurs via release of IL-10, IL-11, IL-13 and type 1 interferons (IFNs) (19). 
IL-12 induces IFNγ release and enhances the cytolytic activity in natural 
killer (NK) cells and T cells. Furthermore IFNγ positively regulates IL-12 
production. In dendritic cells (DCs) IL-12 is induced by previously 
produced IL-12.  The IL-12 receptor, composed of the subunits IL12Rβ2 
and IL12Rβ1, is expressed on Th1 cells, NK cells, naive T cells and DCs 
(15,20,21). Interaction of IL-12p40 occurs via the IL-12Rβ1 and IL-12p35 
associates with IL-12Rβ2 (15). CD4+ T cells are able to develop into Th1 
or Th2 cells according to the cytokines they encounter. IFNγ producing 
Th1 cell differentiation and cell-mediated immunity is mainly promoted by 
IL-12, while the presence of IL-4 drives Th2 cell differentiation (15,22,23).  
Interleukin-23 (IL-23) 
IL-23 is composed of the subunits p40 and p19, which are linked by a 
disulfide bridge, and is produced by monocytes, macrophages, DCs, B 
cells and developing Th17 cells (24,25). Induction of p19 production in 
monocyte derived DCs occurs via CD40 stimulation or TLR2 agonists, 
such as peptidoglycan (26). IL-23 induces Th1 activation and Th17 
polarization and proliferation, which is blocked by IL-27 (4,27). IFNγ and 
IL-12 production is increased in DCs, when treated with IL-23 (28). In a 
mouse model the IL-23 receptor was also found in CD4+CD45RBlow 
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memory T cells and Th17 cells. IL-23 leads to IL-17 production in activated 
CD4+ T cells (29). The IL-23 receptor comprises the subunits IL23R and 
IL12Rβ1. IL-23R has an extracellular N-terminal immunoglobulin (Ig) –like 
domain and two cytokine receptor domains similar to the IL-12 receptor 
subunit IL-12Rβ2. Human memory and activated T cells and NK cell lines 
express the IL-23 receptor, as well as monocytes, macrophages and 
myeloid DCs express it but only at low levels (30). 
Interleukin-27 (IL-27) 
IL-27 consists of a p28 subunit and an EBI3 subunit. This cytokine is 
produced by monocytes, macrophages, DCs, when stimulated via pattern 
recognition receptors, and B cells. It mediates Th1 cell proliferation by 
inducing IL-12Rβ2 in CD4+ T cells (31). It synergizes with IL-12 and 
promotes IFNγ production. By inducing the production of IL-1 and TNFα in 
monocytes and mast cells and additionally IL-18 and IL-12 in monocytes 
IL-27 plays a role in innate immunity. Cytokine production is suppressed 
by IL-27 in activated T cells (32). IL-2 production is limited by IL-27 and 
also IL-12 to ensure Th1 differentiation (31,33). IL-27 blocks IL-23 induced 
Th17 polarization and proliferation and inhibits the differentiation of Th17 
cells (27). B cell differentiation and immunoglobulin production is also 
influenced by IL-27 by inducing only the proliferation of activated naive B 
cells but not memory B cells (31,34). The activity of NK cells is augmented 
by IL-27. This is independent of IFNγ production (31,35). In monocytes, IL-
27 mediates the increase of the major histocompatibility complex class I 
and II (MHC I/II) expression as well as the expression of transporter 
associated with antigen processing-1 (TAP-1) and β2 microglobulin (36). 
Therefore IL-27 may enhance antigen presentation in these cells. The IL-
27 receptor is composed of the subunits WSX-1 and gp130 (4).  
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1.4   Interleukin-35 (IL-35) 
Recently, IL-35, a new cytokine, belonging to the IL-12 cytokine family, 
was described (11,37). EBI3, which also serves as a subunit of IL-27, and 
p35, being a part of IL-12 as well, are the described subunits of IL-35.  
Initially the interaction of EBI3 and p35 was described in human placental 
trophoblasts (11,38).  
IL-35 has been shown to expand murine CD4+CD25+FoxP3+ regulatory T 
cells (Tregs), if T cells are cultivated under strong inductive conditions with 
polyclonal T cell receptor (TCR) activation and the presence of co-
stimulatory signals. Due to its suppressive function on the proliferation of 
murine CD4+CD25- effector T cells and the inhibiting effect on the 
differentiation of Th17 cells and IL-17 production, IL-35 is assumed to 
have anti-inflammatory activity (37). CD4+CD25+FoxP3+ Tregs express 
EBI-3 and IL-12α/p35 at higher levels then CD4+ effector T cells. In a 
mouse model IL-35 is produced by Tregs and contributes to their 
suppressive function. It was also described that EBI3 is a downstream 
target of FoxP3, a transcription factor that is required for Treg 
development and function. EBI3-/- and p35-/- deficient Tregs have 
significantly reduced regulatory activity in vitro and fail to control 
homeostatic proliferation (39). The suppressive function of murine Tregs 
and the production of IL-35 and IL-10 to a lesser degree in Tregs 
increases significantly when they are in contact with conventional T cells 
(40). 
It has been described that human CD4+CD25+FoxP3+ Tregs do not 
constitutively express IL-35. The analysis of IL-35 expression was 
performed by using only EBI3 detection (41).  IL-35 does not contribute to 
the suppressive function of FoxP3 induced human Tregs (42). Recently 
we could demonstrate that dendritic cells, activated with human rhinovirus 
(R-DCs), induce FoxP3 independent T regs that release an inhibitory 
factor (43). Human rhinovirus causes the common cold, which is one of 
the most frequent infections worldwide. HRV primarily infect the ciliated 
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trophoblasts and the levels of EBI3 are strongly up-regulated in sera from 
pregnant women (47). Intestinal epithelial cells, as initial APCs, 
constitutively express EBI3, comparable to p35, and the expression level 
is up-regulated through IL-1α or TNFα addition. In contrast, the p35 level is 
also increased in the presence of IFNγ (48). It is proposed that free, latent 
EBI3 homodimer produced by antigen presenting cells (APCs) acts as an 
antagonist of IL-27 and therefore prevents any further IL-27 stimulation of 
naive T cells (46). It was demonstrated that the lack of EBI3 in mice has 
no influence on the number of B cells and T cells but causes a reduced 
number of invariant natural killer T cells (iNKT). EBI3 deficient mice show 
a decrease of IL-4 production and thus a diminished Th2 rate. They 
express higher levels of IL-17, RORγt, a Th17 transcription factor, and IL-
22. It is suggested that EBI3 is a negative regulator of Th17 development 
(49,50). Sensitisation of EBI3-/- mice with ovalbumin leads to a less severe 
airway hyper-responsiveness, decreased numbers and degranulation of 
eosinophils and a significantly reduced number of VCAM-1+ cells in the 
lungs than in wild type mice. Inhibition of EBI3 expression in DCs of the 
lung after ovalbumin challenge leads to an increased release of IL-10 and 
IL-12 while not expressing IFNα in CD11c+ cells (51). Sauer et al. 
demonstrated that targeting EBI3 in mice leads to a T-bet mediated 
antitumor CD8+ T cell responses in the lung (52). EBI3 deficient mice that 
were infected with Leishmania major show approximately threefold 
increases lesion volume and a greater parasite number in dermal lesions 
compared wild types. They indicate increased IL-4, IL-10 and IL-23 and 
decreased IFNγ levels (53). For an acute myeloid leukemia cell line it was 
described that IL-18 induces, beside Th1 signature parameters such as T-
bet and IFNγ, an up-regulation of EBI3 in the KG1 cell line (54). EBI3 
possibly plays a role in atherogenesis, because it was proposed that in 
atheromatous lesions, smooth muscle cells express EBI3, as well as p28 
and p35, which is up-regulated as response to proinflammatory factors like 
TNFα and IFNγ (55). IFNβ is described to inhibit the expression of p35 and 
to enhance that of EBI3 in immature human DCs (56). EBI3 is strongly 
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induced through stimulation of TLR2, TLR4 and TLR9 in primary DCs (57). 
For EBI3 induction the myeloid differentiation factor 88 (MyD88), 
NFkappaB and PU.1, which binds to the promoter region, are required as 
well (57). 
1.5 Dendritic cells 
Dendritic cells (DCs) were first described in human skin as cutaneous 
nerve cells by Paul Langerhans (58,59) and later discovered in mouse 
spleen (59,60). DCs are bone marrow derived leukocytes (61) and can be 
classified into two types including myeloid DCs and plasmacytoid DCs.  
Myeloid DCs can be further divided into blood monocyte derived DCs 
(moDCs), dermal or interstitial DCs and Langerhans cells (LCs) (59). DCs 
are APCs and are able to initiate and modulate immune response. They 
efficiently stimulate B cells and T cells. 
The precursor of moDCs is the CD14+ monocyte in the peripheral blood. 
Monocytes differentiate after IL-4 and granulocyte macrophage colony-
stimulating factor (GM-CSF) addition into CD14-, CD11c+, CD83+ and 
HLA-DRbright DCs (59,62,63). Dermal or interstitial DCs and LCs are not 
located in the blood but reside in places in the body where the immune 
system first of all has to act against infectious compounds. Thus, LCs 
localize to epithelial surfaces of skin and mucosa and the dermal or 
interstitial DCs localize to the subepithelial tissues of the dermis in skin 
and the interstitia of solid organs (59). Plasmacytoid DCs can be identified 
as lineage negative, HLA-DRbright, BDCA-2+, BDCA-4+ and CD123bright 
cells. They can be fully activated via IL-3 and CD40 ligand (CD40L) or 
microbial product stimulation (59).   
DC maturation 
Upon activation, DCs migrate to lymphoid tissues such as the spleen and 
the lymph nodes. The cells lose their adhesiveness for epithelia and start 
to express the chemokine receptor CCR7, which is specific for 
chemokines produced in the T cell zones of lymph nodes. DC maturation 
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is mediated through proinflammatory cytokines such as TNF-α, and by 
TLR- and CD40L-dependent signals (62,64), which upregulate the 
costimulatory molecules CD80 and CD83, that are transported together 
with major histocompatibility complex (MHC) class II molecules to the cell 
surface where they remain associated within membrane microdomains 
(65). After that maturation is completed they attract T and B lymphocytes 
by releasing chemokines (2,66). Immature DCs or DCs that present self-
antigens induce tolerance in T cells whereas mature DCs or DCs that 
present foreign antigens induce immunity and naive T cell proliferation in 
vitro. The phenotype of mature DCs is associated with an increased 
expression of MHC and T cell co-stimulatory molecules such as CD80 and 
CD86, high capacity to present antigens captured at the time of receiving 
the maturation stimulus, but incapacity to process and present 
subsequently encountered antigens (67).  
Antigen processing and presentation 
Antigens are captured by immature DCs via phagocytosis, endocytosis, 
pinocytosis and specific receptors, such as mannose receptor or TLRs 
(59). After antigen capturing these proteins are processed into peptides 
capable of binding to MHC molecules (2). DCs get activated by antigen 
uptake and processing and through cytokines that serve also as response 
to innate immunity. After activation the ability to capture antigens rapidly 
declines (66). 
There are two different pathways of antigen processing in APCs. Antigens 
that are presented by MHC class II are infiltrated into the cells and 
processed in the endocytotic pathway. Internalized antigens are located in 
the endosomes. These endosomes fuse with lysosomes where the 
antigens are degraded into small peptides. MHC class II molecules are 
synthesized in the endoplasmic reticulum (ER) and transported to 
endosomes with an associated protein called the invariant chain, which 
occupies the peptide-binding sides of the newly synthesized class II 
molecules. The invariant chain is removed from MHC class II molecules 
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and antigenic peptides are then able to bind the available peptide binding 
clefts of the MHC II molecules. MHC class II molecules are stabilized by 
the bound peptides and the stable peptide-class II complexes are 
delivered to the surface of the DC, where they are displayed for 
recognition by CD4+ T cells (2).  
MHC class I molecules present peptides that derive from cytosolic 
proteins. Foreign cytosolic antigens may be the products of viruses or 
other intracellular microbes. These cytosolic proteins get proteolysed into 
peptides by the proteasome. The generated peptides are translocated by 
the TAP transporter into the ER, where they bind to newly synthesized 
MHC class I molecules. The peptide – MHC class I complex is delivered to 
the surface of the APC where the antigen is presented to CD8+ T cells 
(2,66). All nucleated cells have MHC I but only APCs express MHC II. 
IL-10 and DCs  
IL-10 acts as an inhibitor of DCs and is thus involved in the control of 
innate immune reactions and cell-mediated immunity. It suppresses the 
production of IL-12 by DCs and therefore the production of IFNγ. It also 
inhibits the expression of co-stimulators and MHC class II molecules on 
these cells, which causes an inhibition of T cell activation and proliferation 
(2). IL-10 is expressed, secreted and differentially regulated by a variety of 
cell types, including T cells, monocytes/macrophages, DCs, and epithelial 
cells, usually after an activation stimulus. Functionally, IL-10 acts on a 
wide variety of cells, including B cells, NK cells, cytotoxic and helper T 
cells, mast cells, granulocytes, DCs, keratinocytes and endothelial cells 
(68,69). 
1.6   T cells 
The precursors of T cells arise in the bone marrow and migrate into the 
thymus. T cells recognize the antigen presented by an APC and as 
response to that can either destroy the cells that present the antigen or 
release cytokines to activate other cells or fall in anergy, because of 
recognizing self-antigen. Naive T cells are inexperienced T cells that have 
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yet to see their cognate antigen and get activated. TCR engagement in an 
inflammatory cytokine milieu induces the cell to undergo numerous 
changes, including chromatin remodelling and DNA methylation 
modifications, leading to the induction or repression of transcription factors 
in differentiated cell subsets (70,71). This in turn results in the differential 
expression of cell-surface receptors and cytokines. T cells are further 
divided into two types: CD4+ T cells or Th cells provide “help” to B cells 
and other T cells in directing B- and T cell responses and CD8+ T cells or 
cytotoxic T cells owing to their high expression of IFNγ and granzymes. Th 
cells have important roles in combating infections and cancers and 
dysregulation of their function can lead to chronic inflammatory diseases 
(71). 
1.7   T cell activation 
T cells can recognize the antigens presented by DCs when they contact 
these cells. The area where these two cell types establish the contact is 
termed the immunological synapse, where the T cell receptor (TCR) 
interacts with the MHC-peptide complex and co-stimulatory molecules 
aggregate (72). The ability of T cells to clonally expand depends on the 
strength of the signals received by TCR MHC-peptide complex interaction 
(signal 1) and co-stimulatory molecules (signal 2) (73). The amount of 
signal that T cells receive is dependent on the level of peptide-MHC 
complexes, the level of co-stimulatory molecules that amplify the signaling 
process, and the stability of the synapse (74). For an efficient T cell 
activation the signaling via the TCR requires the interaction of co-
stimulatory molecules, like CD28 with CD80 or CD86. Activated T cells 
produce IL-2 which causes a rapid T cell proliferation and can act in an 
autocrine and paracrine way. A third signal is acquired for T cell 
differentiation, which is elicited by DCs through cytokine secretion. T cells 
that receive a short TCR signaling in the absence of IL-12 proliferate, but 
cannot differentiate into effector cells. T cells that receive a prolonged 
TCR signal in presence of IL-12 differentiate into Th1 cells and those in 
presence of IL-4 differentiate into Th2 cells. Th1 and Th2 cells acquire the 
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capacity to migrate to inflamed non-lymphoid tissues to execute their 
effector functions (74).  
1.8   Immunological Synapse 
The immunological synapse is formed between a T cell and an APC, e.g. 
the DC, via the TCR and peptide – MHC complex. The mature 
immunological synapse is defined by a specific pattern of receptor 
segregation with a central cluster of TCRs surrounded by a ring of integrin 
family adhesion molecules (75,76). After contact between T cell and DC is 
established, three different physical states can be achieved, all of which 
have an impact on contact duration, receptor engagement and 
downstream signalling (77).  
The development of the immunological synapse is characterized by 5 
phases. The first phase of immunological synapse formation occurs when 
moving T cells recognize peptide–MHC complexes, leading to a transient 
arrest in migration. The second phase is the most important phase for 
signal induction and is therefore crucial for determining the outcome of the 
T cell–APC interaction. Within the first few seconds of contact, calcium 
signalling, followed by recruitment of signalling molecules is observed 
(77). At the same time, the TCR, CD4 and other receptors (such as CD28) 
move to the contact zone, where the dynamic signalling platform is being 
assembled (77,78). In the third phase a mature immunological synapse 
forms at the cell–cell junction within 5–30 minutes of continuous T cell–
APC interaction. Maturation is defined by molecular segregation, which 
leads to a central zone that contains TCR and CD3 and, at least 
temporarily, CD28, CD2, CD4 (transient), CD45 (transient) and cytotoxic 
T-lymphocyte antigen 4 (CTLA-4). In the fourth phase, after sustained 
signalling, the TCR is internalized from the central zone into cytoplasmic 
vesicles, thereby limiting its availability at the interaction plane. 
Immunological synapse resolution occurs when the T cell and the APC 
separate in the fifth and last phase (77). 
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.  
Figure 3: Immunological synapse (Friedl P. et al., 2005, Nat Rev Immunol, 5:532-45) 
 
1.9   T cell subsets 
CD4+ T cells / T helper cells 
CD4+ T cells play a central role in immune protection. This is 
accomplished by their capacity to help B cells to produce antibodies, to 
induce macrophages to develop enhanced microbicidal activity, to recruit 
neutrophils, eosinophils, and basophils to sites of infection and 
inflammation, and, through their production of cytokines and chemokines. 
Several types of the CD4+ T cell population represent alternative patterns 
of differentiation. Naive CD4+ T cells can differentiate into distinct 
populations by the pattern of signals they receive during their initial 
interaction with antigen. These populations are Th1, Th2, Th17, induced 
regulatory T (iTreg) cells, and the recently described Th9 and Th22 cells. 
Th1 cells are regarded as critical for immunity to intracellular 
microorganisms and Th2 cells for immunity to many extracellular 
pathogens (79,80). 
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Figure 4: CD4+ T cell subsets (Zhu, J. and Paul, W.E., 2008, Blood, 112:1557-69) 
 
Th1 cells mediate immune responses against intracellular pathogens (79). 
In humans, they play a particularly important role in resistance to 
mycobacterial infections. Th1 cells are also responsible for the induction of 
some autoimmune diseases (80). They produce IFNγ, important in 
activating macrophages to increase their microbicidal activity (81), 
lymphotoxin α (LTα), a marker for the disease progression in multiple 
sclerosis patients (82), and IL-2, important for CD4+ T cell memory (80). 
Th1 cells express the IL-12 receptor (IL-12R) as well as the IL-18 receptor 
(IL-18R). The subunit IL-12R β1 is constitutively expressed on naive CD4+ 
T cells and increases in Th1 cells (83) and IL-12R β2 expression is 
induced by TCR activation and then maintained by IL-12 and IFNγ 
stimulation (84). Although IL-18 is not involved in the differentiation of Th1 
cells, it can synergize with IL-12 inducing IFNγ, implying that IL-18 plays 
an important role in Th1 responses (80,85). The main transcription factor 
for Th1 cells is T-bet, which is Stat1 and then IFNγ induced and up-
regulated during Th1 differentiation. Th1 polarization and proliferation can 
be induced by the IL-12 secretion of APCs as a result of their activation. 
This also promotes Th1 cell differentiation by acting on both NK cells and 
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T cells. Collaboration between IFNγ and IL-12 induces full Th1 
differentiation (80,86).  
Th2 cells mediate host defense against extracellular parasites including 
helminths (79). They are important for the induction and persistence of 
asthma and other allergic diseases. Th2 cells produce the cytokines IL-4, 
IL-5, IL-9, IL-10, IL-13, IL-25, and amphiregulin (80). These cells express 
several surface markers including the IL-4 receptor (IL-4R). During 
differentiation the subunit of this receptor IL-4Rα is up-regulated by IL-4. 
T1/ST2 (IL-33Rα) is known as the most important surface marker for Th2 
cells (87) and belongs to the IL-1R superfamily, which also includes IL-
18Rα (80). The most important transcription factor for Th2 differentiation is 
GATA-3, which is induced by IL-4 activated Stat6 (88). In vitro Th2 
differentiation requires IL-4 and IL-2 (89). If IL-4 is provided exogenously 
GATA-3 expression is induced by Stat6 activation, but if IL-4 is not 
provided it can be produced by naive CD4+ T cells in limited amounts after 
TCR-mediated GATA-3 transcription and IL-2-mediated Stat5 activation 
(90). The collaboration of Stat5 and GATA-3 is responsible for full Th2 
differentiation in vitro (91). 
Th17 cells mediate immune responses against extracellular bacteria and 
fungi by releasing IL-17 which recruits and activates neutrophils (92). They 
participate in the induction of many organ-specific autoimmune diseases. 
Th17 cells produce IL-17a, IL-17f, which are genetically linked and often 
co-expressed, IL-21 and IL-22. IL-17a has an important role in inducing 
inflammatory responses, because it is able to stimulate inflammatory 
cytokines such as IL-6. Th17 cells also secrete IL-21, a stimulatory factor 
for Th17 differentiation, which also acts on CD8+ T cells, B cells, NK cells 
and DCs (93). Th17 cells express high levels of IL-23R (25). The most 
important transcription factor of Th17 cells is RORγt (94). Stat3, the major 
signal transducer for IL-6, IL-21 and IL-23, is indispensable for IL-17 
production and deletion of Stat3 results in the loss of IL-17 producing cells 
(80,95). A combination of IL-6, induced by TLR signalling, and TGF-β 
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induces Th17 differentiation, IL-21 production and the expression of IL-
23R and RORγt (96,80). IL-6 can be replaced by IL-21 for inducing RORγt 
and IL-17 expression (25). IL-23, initially proposed as the differentiation 
factor for Th17 cells, fails to induce Th17 differentiation from murine naive 
CD4+ T cells but is critical for Th17 cell survival and/or for maintaining their 
function. Therefore, Th17 cell differentiation consists of 3 stages: a 
differentiation stage, based on TGFβ and IL-6; an amplification stage, 
mediated by IL-21; and a stabilization stage due to IL-23. Importantly, all 
three cytokines, IL-6, IL-21, and IL-23, activate Stat3 (80). 
Regulatory T cells 
T regs are very important for maintaining self-tolerance and regulating 
immune responses (97). T regs can be divided into two groups, first, the 
natural occurring CD4+CD25+ T regs, which express the transcription 
factor FoxP3 their whole living already in the thymus and, second, the 
inducible T regs, in which FoxP3 is induced in the periphery. Additionally, 
two subsets of inducible T regs with regulatory and suppressive function 
were described, Tr1 cells and Th3 cells, believed to suppress immune 
responses through the production of IL-10 and TGF-β (98,99). Natural T 
regs are described to inhibit the development of autoimmune disease 
elicited by T regs depletion and to suppress the proliferation of antigen-
stimulated naive T cells in vitro (100). T regs produce and release several 
cytokines such as TGF-β, IL-10 or IL-35. It was suggested that T regs act 
in cell-contact dependent manner, because they fail to suppress 
proliferation of responder T cells, when they were separated through a 
semi-permeable membrane and the neutralisation of IL-10 and TGF-β 
does not avoid the in vitro suppression (100,101,102). TGF-β is believed 
to act as a suppressive mediator in a membrane-bound form (103) and 
activates Smad3 while TCR stimulation induces NFAT activation, both 
promote FoxP3 expression. FoxP3 expression is also induced by Stat5 
activation, what is mediated by IL-2 (80).  
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Beside this, TGF-β together with the mode of antigen-presentation also 
initiates the differentiation of inducible T regs from CD4+ T cells (80). Tr1 
cells can be generated by addition of IL-10 and they further produce high 
levels of IL-10. They do not express FoxP3 and are able to develop in the 
absence of natural T regs. But Tr1 cells inhibit T cell proliferation with 
comparable efficiency to natural T regs. Th3 cells were found after orally 
tolerizing mice with low antigen doses. These cells were described to 
produce TGF-β (99). 
CD8+ T cells  
CD8+ T cells are key players in mediating immunity to intracellular virus 
pathogens and tumors. CD8+ T cells recognize antigen in the context of 
MHC class I inducing CD8+ T cell activation, proliferation and 
differentiation into effector cytotoxic T lymphocytes (CTLs); this is known 
as the primary response (104). The help of CD4+ T cells is essential for 
CTL priming and confers a key feature of immune memory (105). After the 
primary response, most effector CD8+ T cells die, but some rest as long-
lived memory cells. Memory cells are able to respond with enhanced 
efficacy to a second challenge with the same antigen (secondary 
response) in the absence of T cell help (104,105). The CD8+ T cells that 
are not helped by CD4+ T cells can mediate effector functions such as 
cytotoxicity and cytokine secretion upon re-stimulation, but do not undergo 
a second round of clonal expansion (105,106,107).  
The effector functions of CD8+ T cells are presented by killing their targets 
(infected cells) via the release of cytoplasmic granules that comprise 
membrane pore forming proteins. The killing occurs via two mechanisms 
that require direct contact between the effector and target cells. In the first 
pathway, cytoplasmic granule toxins and granzymes (family of structurally 
related serine proteases) are secreted by exocytosis and together induce 
apoptosis of the target cell (108,109). The granule-exocytosis pathway 
activates efficiently cell-death pathways that operate through the activation 
of apoptotic cysteine proteases (caspases), but it also leads to cell death 
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in the absence of activated caspases (109,110,111).The second pathway 
involves the engagement and aggregation of target-cell death receptors, 
such as FAS, by their cognate ligands, such as FAS ligand (FASL), on the 
killer-cell membrane, which results in classical caspase-dependent 
apoptosis (109,112). 
CD2-/low T cells 
In 1988 a subset of T cells lacking CD2 expression or only expressing 
CD2 in very low amounts was identified. CD2 was thought to be 
expressed on all T cells just like CD3. These CD2-/lowCD3+ T cells were 
first described in fetal human spleen and thymus (113), and in a subset of 
CD3+TCR-γ/δ+ peripheral blood T cells from one individual (114). Also 
CD2-/lowCD3+ TCR-α/β+ peripheral blood T cells were isolated and these 
cells can be induced to proliferate, produce IL-2 and display cytotoxic 
effector function (115). These cells show a mostly CD4/CD8 double 
negative, CD3+TCR- immature phenotype. They produce the type 2 
cytokines IL-13, IL-4 and IL-5, but not IFNγ or IL-10, and upon culture with 
IL-12 and TCR-mediated stimuli, differentiate to functionally mature IFN-γ+ 
cells (116). This population is previously described to represent <0,1% of 
the T cells in freshly isolated lymphocytes. It was described that peripheral 
CD2-/low T cells are possibly early differentiated T cells that may undergo 
extrathymic maturation, and potentially contribute to maintain the 
peripheral naive T cell pool (117). But the function of these cells is unclear. 
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2 AIM OF THIS STUDY 
 
The cytokines of the IL-12 family have similar structures and similar 
functions. They are produced by APCs, especially DCs, and act mainly on 
T cells in different kind of ways. The recently described IL-35 differs from 
the other cytokines of the IL-12 family. In the mouse system IL-35 is 
promoted to have anti-inflammatory function and is produced by 
CD4+CD25+FoxP3+ regulatory T cells (T regs) and contributes to their 
suppressive function (39). In the human system the characterisation of IL-
35 is not comparable with that in mice, because IL-35 is not constitutively 
expressed by T regs (41). We recently could demonstrate that IL-35 is 
produced by T cells that were in contact with human rhinovirus activated 
DCs (R-DCs) (43). So at this time point the role of IL-35 is not entirely 
clear. What we want to find out in this study is if IL-35 does act on DCs, on 
T cells or on both cell types and how it affects these cell types.  
 
Figure 5: Scheme of this aim 
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3 MATERIAL AND METHODS 
3.1 Reagents and chemicals 
3.1.1 List of mouse anti-human mAbs 
Specificity Clone Isotype Source 
T cell stimulation 
   
CD3 OKT3 IgG2a Jansen-Cilag, Vienna 
CD28 15E8 IgG1 
Caltag Laboratories, Burlingame, 
CA 
CD63 
CD63-
11C9 
IgG3 
Otto Majdic, Institute of 
Immunology, Vienna 
Staining 
   
Calf intestine 
alkaline 
phosphatase 
Viap-2D5 IgG1 
Otto Majdic, Institute of 
Immunology, Vienna 
CD1a VIT6B IgG1 
Otto Majdic, Institute of 
Immunology, Vienna 
CD2 TS2/18 IgG1 
Otto Majdic, Institute of 
Immunology, Vienna 
CD3 Ucht1 IgG1 
Otto Majdic, Institute of 
Immunology, Vienna 
CD14 VIM13 IgM 
Otto Majdic, Institute of 
Immunology, Vienna 
CD40 G28-4 IgG1 
American Type Culture 
Collection (ATCC), Rockville, 
Tenesse 
CD80 7-480 IgG1 
Otto Majdic, Institute of 
Immunology, Vienna 
CD83 HB15e IgG1 BD, New Jersey, NJ 
CD86 BU63 IgG1 Caltag-Medsystems Ltd , 
Buckingham 
MHC I W6/32 IgG2a ATCC, Rockville, Tenesse 
MHC II – HLA-DR L243 IgG2a 
Otto Majdic, Institute of 
Immunology, Vienna 
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B7-H1 
 
5-272 
 
IgG1 
 
Otto Majdic, Institute of 
Immunology, Vienna 
B7-H3 13-I/241 IgG1 
Otto Majdic, Institute of 
Immunology, Vienna 
Siglec-1 7-239 IgG1 
Otto Majdic, Institute of 
Immunology, Vienna 
S100-A4 8-9 IgG1 
Otto Majdic, Institute of 
Immunology, Vienna 
Mxa 383-7D4 IgG1 
Otto Majdic, Institute of 
Immunology, Vienna 
p35 27537 IgG1 
R&D Systems Inc., Minneapolis, 
MN 
EBI3 polyclonal  Abnova, Taipeh, Taiwan 
 
3.1.2 List of recombinant cytokines 
Cytokine Trade name Source 
IL-35:Fc 522-140-C010 
Alexis Biochemicals, San 
Diego, CA 
Human recombinant IL-10 217-IL 
R&D Systems Inc., 
Minneapolis, MN 
 
3.1.3 List of stimuli  
Stimulus Concentration Source 
HRV14 5 TCID50 Joachim Seipelt 
IFNα 100 U/ml 
PBL Biomedical 
Laboratories, 
Piscataway, NJ 
LPS 1 µg/ml Sigma-Aldrich 
polyIC 20 µg/ml Sigma-Aldrich 
Zymosan A, S. cerivisiae 30 µg/ml Sigma-Aldrich 
 
32 
 
3.1.4 List of cell lines 
Cell line Cell type Source 
HeLa Ohio Human cervix carcinoma ATCC 
A431 Human epidermoid carcinoma ATCC 
SCC4 
Human squamous cell carcinoma 
(tongue) ATCC 
SCC9 
Human squamous cell carcinoma 
(tongue) ATCC 
Jurkat Human T cell leukemia ATCC 
Daudi 
Human Burkitt´s  lymphoma 
(EBV+) ATCC 
Otma EBV transformed B cells 
Otto Majdic, Institute of 
Immunology, Vienna 
 
3.2 Preparation of peripheral blood mononuclear cells  
Peripheral blood mononuclear cells (PBMNCs) were isolated from fresh 
blood (Buffy coats, Red Cross Vienna) from healthy donors. Blood was 
diluted with RPMI1640 medium (Gibco Ltd., Paisley, Scotland) 
supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin (Sigma-Aldrich, St. Louis, MO) and 10 U/ml heparin (EBEWE 
Pharma, Unterach, Austria). The diluted blood was then overlaid above 15 
ml Ficoll-Paque (Axis-Shield PoC AS, Oslo, Norway) to a final volume of 
50 ml. For density gradient centrifugation the tubes were centrifuged at 
900 g for 30 min at 25°C without brake. In the Fico ll gradient cells are 
separated due to their different density. The pellet contains mainly 
erythrocytes and leukocytes, whereas the white interphase contains 
PBMNCs consisting of lymphocytes and monocytes and the upper phase 
contains serum. The interphase with the PBMNCs was then collected into 
fresh tubes and washed twice with MACS buffer (1% PBS supplemented 
with human serum albumin (Aventis Behring, Vienna, Austria) and 5 mM 
EDTA (Gibco Ltd., Paisley, Scotland).  
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3.3 Magnetic-activated cell sorting (MACS) 
Magnetic-activated cell sorting (MACS) is a method for the selective 
enrichment or depletion of cells which express a cell type specific surface 
protein. Therefore cells can be labelled with biotin coupled antibodies 
directed against this specific molecule. These labelled cells can be 
targeted with a secondary antibody coupled to magnetic beads directed 
against the biotin residues on the primary antibody. Thus specific cells 
labelled with the magnetic beads in a suspension can be selectively 
retained in a column when a magnetic field is delivered. In this strong 
magnetic field the cells labelled with paramagnetic beads stack to the iron 
mesh and were retained while non-labelled cells passed through. Retained 
cells were eluted by removing the column from the magnetic field. 
3.4  Monocyte isolation 
For the isolation of monocytes up to 1 x 109 PBMNCs were incubated with 
15 µg/ml of biotinylated anti-CD14 (VIM13, MEM18). Therefore PBMNCs 
were resuspended in 750 µl MACS buffer and incubated with 250 µl 
biotinylated antibodies for 15 min at 4 °C. To remo ve unbound antibodies 
the cells were washed twice with MACS buffer and again resuspended in 
750 µl buffer. Then 250 µl streptavidin MicroBeads (Miltenyi Biotec, 
Bergisch Gladbach, Germany) were added to the suspension and 
incubated for 15 min at 4°C. In the meantime a CS c olumn (Miltenyi 
Biotec), which can be loaded with a maximum of 109 cells, was placed 
onto a VarioMACS apparatus and equilibrated with 40 ml MACS buffer.  
Monocytes were positively enriched. The PBMNCs incubated with the 
CD14 mAb and the streptavidin MicroBeads were loaded onto the CS 
column. CD14+ monocytes remained in the column, CD14- cells were 
washed out with 40 ml MACS buffer. The flow through was collected as 
monocyte negative fraction containing T cells, B cells and NK cells 
(fraction 1).  
The column was removed from the magnetic field and the MACS buffer 
was added in 10ml portions alternating through the side syringe or loaded 
on the top of the column. After each addition step the column was put 
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back into the magnet and about 10ml were let to run through. These steps 
were repeated until a volume of 50ml had passed through (fraction 2).  
For monocytes collection the column was removed from the magnet and 
MACS buffer was added several times into the reservoir. After each step 
the liquid was taken off through the lateral valve using a syringe. These 
steps were repeated until the collected volume came to 40ml (fraction 3). 
The third fraction was centrifuged for 5´ at 900g, resuspended and the 
number of monocytes was determined.  
The purity (> 95%) of monocytes was controlled by immunofluorescence 
analysis. Double-staining with directly labeled Antibodies using CD4-
PE/CD3-FITC; CD8-PE/CD3-FITC, CD19-PE/CD3-FITC, CD56-PE/CD3-
FITC, HLA-DR-PE/CD3-FITC, CD14-PE/HLA-DR-FITC. 
3.5  T cell isolation 
To isolate T cells from up to 1 x 109 PBMNCs the MACS technique was 
used. T cells were isolated by collecting the flow through of PBMNCs 
depleted by using different mAbs at a concentration of 10 µg/ml containing 
anti-CD14 (MEM 18) for collecting monocytes, anti-CD16 (3G8) for binding 
granulocytes and NK cells, anti-CD19 for B cells (BU 12) and anti-CD33 
(4D3) for monocytes, thrombocytes and myeloid progenitors (negative 
selection). Freshly isolated PBMNCs were resuspended in 750 µl MACS 
buffer and incubated with 250 µl biotinylated antibodies for 15 min at 4 °C. 
To remove unbound antibodies the cells were washed twice with MACS 
buffer and again resuspended in 750 µl buffer. Then 250 µl streptavidin 
MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) were added to 
the suspension and incubated for 15 min at 4°C. In the meantime a CS 
column (Miltenyi Biotec), which can be loaded with a maximum of 1x109 
cells, was placed onto a VarioMACS apparatus and equilibrated with 40 ml 
MACS buffer. PBMNCs were loaded onto the column, T cells were eluted 
and washed until a volume of 50 ml was reached.  The collected T cells 
were centrifuged for 5´ at 900g, resuspended and the number of cells was 
determined.  
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The purity (> 95%) of T cells was controlled by immunofluorescence 
analysis. Double-staining with directly labeled Antibodies using CD4-
PE/CD3-FITC; CD8-PE/CD3-FITC, CD19-PE/CD3-FITC, CD56-PE/CD3-
FITC, HLA-DR-PE/CD3-FITC, CD14-PE/HLA-DR-FITC. 
3.6 Generation of monocyte derived DCs  
DCs were generated by culturing purified monocytes for 6 days with a 
combination of 50 ng/ml GM-CSF and 100 U/ml IL-4 in RPMI1640 (Gibco 
Ltd., Paisley, Scotland) supplemented with 10% characterized FCS 
(Sigma-Aldrich), 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin (Sigma-Aldrich). Maturation of DCs was initiated by adding 1 
µg/ml LPS (Sigma Aldrich, St. Louis, MO) for 24 h. 
3.7 Generation of human rhinovirus treated DCs (R-DCs) 
For the generation of R-DCs monocyte derived DCs, cultured at a density 
of 1x106 cells/ml, were treated with human rhinovirus 14 (HRV14) at a 
dose of 5 TCID50 for 48 hours. 
3.8 Generation of IL-35 pre-treated DCs (IL-35-DCs) 
Purified monocytes were cultured for 3 days with a combination of 50 
ng/ml GM-CSF and 100 U/ml IL-4 in RPMI1640 (Gibco Ltd., Paisley, 
Scotland) supplemented with 10% characterized FCS (Sigma-Aldrich), 2 
mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin (Sigma-
Aldrich). Then human IL-35 (Alexis Biochemicals, San Diego, CA) at a 
concentration of 2 ng/ml or human recombinant IL-10 (R&D Systems Inc., 
Minneapolis, MN) at a concentration of 20 ng/ml was added and further 
cultured for 3 days to obtain IL-35 or IL-10 pre-treated DCs. Maturation of 
DCs was initiated by adding 1 µg/ml LPS (Sigma Aldrich, St. Louis, MO) 
for 24 h. 
3.9 Freezing and thawing of cells  
Mammalian cells can be stored in liquid nitrogen for prolonged periods of 
time with minimal loss of viability in subsequent cell culture. For that 
purpose, cells were centrifuged, counted, resuspended in freezing medium 
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(RPMI1640 supplemented with 25% FCS and 10% DMSO (Sigma)) and 
adjusted to a cell number ranging from 107 – 5 x 107 cells/ml. 1 ml aliquots 
were filled into cryotubes (Nalgen Nunc International, Roskilde, Denmark) 
and kept overnight at - 80°C in a freezing box fill ed with isopropanol before 
being transferred to liquid nitrogen. 
Cryotubes were thawed in 37°C warm water bath. A re st frozen media was 
left to avoid overheating, that would thaw on ice. When all frozen media 
was dissolved droplets of cell culture medium were added and then cells 
were washed two times with RPMI1640 plus 10% FCS (Sigma-Aldrich), L-
glutamine, penicillin, streptomycin. Thawed cells were counted and 
cultured in medium. 
3.10  Cell Culture conditions  
For cell culture RPMI supplemented with 10%  FCS  (HyClone,  Logan,  
UT),  2  mM  L-glutamine  (NBK,  Novartis Research  Institute,  Vienna),  
100  U/ml  penicillin  and  100  µg/ml  streptamycin (NBK, Novartis 
Research  Institute,  Vienna) was  used. Cells were cultured at 37°C with 
5% CO2. 
3.11  DC and T cell co-culture 
T cells were co-cultured with DCs or R-DCs in a cell ratio ranging from 5:1 
to 10:1 for 3 days. The supernatants of the co-cultures were collected and 
added to a MLR or to a T cell proliferation assay. The cells of the co-
cultures were analysed by FACS. 
3.12  Mixed Leukocyte Reaction (MLR) 
In an allo – MLR lymphocytes from a potential donor are mixed with 
stimulator cells from a potential recipient, i.e. APCs like DCs. If the two cell 
populations are not compatible in their MHC, which means they are 
allogeneic, proliferation of T cells occurs. 
1 x 105 responder T cells were cultivated together with 1 x 104 DCs and 
100 µl of DC/T cell or R-DC/T cell supernatant or 10 ng/ml and 1 ng/ml 
human IL-35 (Alexis Biochemicals, San Diego, CA) in RPMI1640 (10% 
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FCS (Sigma-Aldrich), L-glutamine, penicillin, streptomycin) for 5 days in a 
final volume of 250 µl under standardized cell culture conditions (37°C, 5% 
CO2, humidified atmosphere).  
For the MLR with IL-35-DCs, 1 x 105 responder T cells were cultivated 
together with 1 x 104 DCs, IL-35-DCs or IL-10-DCs with or without LPS in 
RPMI1640 (10% FCS (Sigma-Aldrich), L-glutamine, penicillin, 
streptomycin) for 5 days in a final volume of 250 µl under standardized cell 
culture conditions (37°C, 5% CO 2, humidified atmosphere).  
Each experiment was performed in triplicates in 96-well plates (Costar, 
Sigma Aldrich). On day five 25 µl of 1:20 diluted methyl-3[H]thymidine (1 
µCi/well) (Perkin Elmer, Waltham, MA) was added to the cells and 
incubated for 18 h. The cells were lysed, their DNA collected onto filter-
plates (Perkin Elmer, Wellesley, MA) and after adding 25 µl of Microscint 
scintillation mix (Packard, Meriden, Connecticut) in each well radioactive 
emissions quantified on a Packard microplate scintillation counter. 
3.13   T cell proliferation assays 
T cells were either mock treated or stimulated with anti-CD3 (OKT3), anti-
CD3/CD28 (OKT3/15E3) and anti-CD3/CD63 (OKT3/11C9) mAbs at a 
concentration of 2 µg/ml for 3 days. Experiments were performed in 96-
well cell culture plates. The plates were coated with a volume of 30 µl of 
antibody solution over night at 4°C or for about 2 hours at 37°C. Then the 
antibody solution was removed and the plates were washed twice with 
PBS.  1x105 T cells in RPMI-1640 medium supplemented with 10% FCS 
were added into each well.  Proliferation of T cells was monitored by 
measuring (methyl-3H)-TdR (Perkin Elmer, Waltham, MA) incorporation on 
day 4 of culture. Cells were harvested 18 hours later, and radioactivity was 
determined on a microplate scintillation counter (Perkin Elmer, Wellesley, 
MA). Assays were performed in triplicates. 
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3.14  Staining of surface proteins 
Membrane staining with unconjugated mAb: 
Unspecific binding of mAbs to Fcγ-receptors was blocked by incubation of 
cells with human immunoglobin Beriglobin (Aventis Behring GmbH, 
Vienna). As isotype control VIAP, a calf intestine alkaline phosphatase-
specific antibody was applied. For secondary labelling Oregon Green-
conjugated goat anti mouse antibody was used. Dead cells were excluded 
from analysis by staining with propidiumiodide. 
• PBS/BSA: 1x PBS + 1% BSA 
• Beriglobin (final concentration 20 mg/ml) diluted 1:8 in PBS/BSA (1% v/v 
BSA) (Aventis Behring GmbH, Vienna) 
• Primary antibody: 20 µg/ml 
• Secondary antibody: Oregon Green-conjugated goat-anti-mouse IgG 20 
µg/ml in PBS/BSA (Molecular Probes; Eugene, Oregon) 
First the cell suspension (5 x 105 /assay) was centrifuged for 5 minutes at 
300g and the pellet was resuspended with 50 µl Beriglobin/assay and kept 
10 minutes on ice. Then 20 µl of the antibody were prepared in Micronic-
tubes and 50 µl of the cell suspension was added, mixed and incubated 30 
minutes at 4°C. Each assay was washed twice with PB S/BSA 
(resuspended in PBS/BSA, centrifuged (5 minutes at 300g), the 
supernatant was discarded). 20 µl Oregon Green were added to the cells, 
and again incubated for 30 minutes at 4°C. Each ass ay was washed twice 
with PBS/BSA and the cells were resuspended in 50 µl FACS fluid (Becton 
Dickinson, Franklin Lakes, NJ). The tubes were kept on ice until they were 
analyzed by flow cytometry using a FACScalibur Flow Cytometer (Becton 
Dickinson, Palo Alto, CA) 
 
 
39 
 
Membrane staining with conjugated mAb: 
The cell suspension (5 x 105 /assay) was centrifuged 5 minutes at 300g 
and the pellet was resuspended with 50 µl Beriglobin/assay and kept 10 
minutes on ice. 20 µl of the respective antibody was prepared in Micronic-
tubes and 50 µl of the cell suspension was added, mixed and incubated 30 
minutes at 4°C. Each assay was washed twice with PB S/BSA 
(resuspended in PBS/BSA, centrifuged (5 minutes at 300g), the 
supernatant was discarded) and the cells were resuspended in 50 µl 
FACS fluid (Becton  Dickinson,  Franklin  Lakes,  NJ). The tubes were kept 
on ice until they were analyzed by flow-cytometry. 
3.15  Cytokine binding assay 
Membrane staining with Fc fragment of immunoglobulin conjugated 
cytokines: 
Unspecific binding of cytokines to Fcγ-receptors was blocked by 
incubation of cells with mouse anti-human VIAP, a calf intestine alkaline 
phosphatase-specific antibody. As negative control human 
immunoglobulin Beriglobin (Aventis Behring GmbH, Vienna) was applied. 
For secondary labelling phycoerythrin-conjugated F(ab)2 fragment goat-
anti human IgG, Fcγ specific antibody was used.  
• PBS/BSA: 1x PBS + 1% BSA 
• VIAP: final concentration 20 µg/ml in PBS/BSA  
• Cytokines: 20 µg/ml 
• Secondary antibody: phycoerythrin-conjugated F(ab)2 fragment goat-anti 
human, Fcγ specific IgG 20 µg/ml in PBS/BSA (Jackson 
ImmunoResearch) 
The cell suspension (5 x 105 /assay) was centrifuged for 5 minutes at 300g 
and the pellet was resuspended with 50 µl VIAP/assay and kept 20 
minutes on room temperature. Then 10 µl of cytokines were prepared in 
Micronic-tubes and 50 µl of the cell suspension was added, mixed and 
incubated 30 minutes at 4°C. Each assay was washed twice with 
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PBS/BSA (resuspended in PBS/BSA, centrifuged (5 minutes at 300g), the 
supernatant was discarded). 20 µl of Fcγ specific IgG were added to the 
cells, and again incubated for 30 minutes at 4°C. E ach assay was washed 
twice with PBS/BSA (resuspended in PBS/BSA, centrifuged (5 minutes at 
300g), the supernatant was discarded). The cells were resuspended in 50 
µl FACS fluid (Becton  Dickinson,  Franklin  Lakes,  NJ) and the tubes 
were kept on ice until they were analyzed by flow cytometry using a 
FACScalibur Flow Cytometer (Becton Dickinson, Palo Alto, CA) 
3.16  Immunofluorescence of cytoplasmic proteins 
Cells of the DC and T cell co-culture were harvested and washed with 
PBS/BSA. The pellet was resuspended in 50µl Beriglobin/assay and 50µl 
fixation medium (Bio Research GmbH, An der Grub, Kaumberg, Austria) 
and incubated for 20 minutes at RT. Each assay was washed once with 
PBS/BSA (resuspended in PBS/BSA, centrifuged (5 minutes at 300g), the 
supernatant was discarded). 50 µl permeabilisation medium (Bio Research 
GmbH) and 20 µl mAb were added and incubated 20 minutes at RT.  The 
cells were washed twice with PBS/BSA. 20 µl Oregon Green and 50 µl 
permeabilisation medium were added to the cells, and again incubated for 
20 minutes at RT. The cells were washed twice with PBS/BSA. The 
samples were prepared for immunofluorescence analysis by addition of 
50µl of FACS fluid (Becton Dickinson, Franklin Lakes, NJ). The tubes were 
kept on ice until they were analyzed by flow cytometry using a 
FACScalibur Flow Cytometer (Becton Dickinson, Palo Alto, CA). 
3.17  Flow cytometric analysis 
The FACS technique permits the isolation of different live cell populations 
via their different surface molecules, stained with specific fluorescent 
antibodies. In a flow cytometer, single cells move past the excitation 
source and the light hitting the cells is either scattered or absorbed and 
then re-emitted (fluorescence). This scattered or re-emitted light is 
collected by a detector. The rate of scattered light depends on cell size 
and complexity. The forward scatter determines the diffraction of light and 
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depends on the volume of cells. The sideward scatter determines the 
refraction of light and depends on granularity, size and structure of the 
nucleus and the rate of vesicles of cells.  
3.18 Preparation of protein samples 
0.1 µg or 1 µg of the recombinant IL-35 were mixed with 75 µl 2x Laemmli 
buffer containing 50 µl β-mercaptoethanol / ml (both BIORAD, Hercules, 
CA). Samples were frozen in liquid nitrogen and transferred to -80ºC for 
long term storage. 
The samples were sonicated (15 s) and denatured (5min., 95ºC) before 
SDS-PAGE. 
3.19 SDS-polyacrylamide electrophoresis (SDS-Page) 
SDS Polyacrylamide Electrophoresis allows the separation of proteins 
according to their size. SDS has a very hydrophobic end and a highly 
charged part. Under denaturing conditions SDS masks the charged 
residues of proteins. The protein size was determined by using a protein 
standard of defined molecular weight.  
The gel caster (Hoefer Scientific Instruments, San Francisco, CA) was 
prepared by assembling ethanol-cleaned glass / aluminium oxide plates 
and spacers. The running gel was prepared, cast up to 2 cm below the 
upper edge of the glass plate and covered with 96% ethanol (20 min.). 
After removing residual ethanol, the stacking gel was added and a comb 
carefully placed on top (20 min.). After successful polymerization the 
chambers in the gel apparatus (Hoefer Scientific Instruments, San 
Francisco, CA) were filled with 1x running buffer (25 mM Tris base, 192 
mM glycine, 0.1% SDS). Samples (10-12 µl) were loaded along with 5 µl 
SeeBlue Plus2 prestained marker as protein standard (Invitrogen GmbH, 
Lofer, Austria). Empty slots were filled with Laemmli buffer. Gels were run 
constant at 60 V until the running gel was reached. Then the voltage was 
set to 120 V till proper separation. 
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Running gel (10%, for 2 gels): 
4.8 ml aqua dest. 
3 ml Tris HCl 1.5 M pH 8.8 
4 ml Rotiphorese Gel 30 solution (Roth, Karlsruhe, Germany) 
100 µl 10% SDS 
100 µl 10% APS 
8 µl TEMED 
Stacking gel (4%, for 2 gels): 
2 ml aqua dest. 
840 µl Tris HCl 0.5 M pH 6.8 
400 µl Rotiphorese Gel 30 solution (Roth, Karlsruhe, Germany) 
35 µl 10% SDS 
35 µl 10% APS 
4 µl TEMED 
3.20 Western Blot analysis 
Blotting buffer (1x): 
100 ml stock (25mM Tris, 192mM glycine) 
100 ml methanol 
800 ml aqua dest. 
PBS-T (wash solution): 
1x PBS + 0,05% Tween-20 
Blocking solution: 
5% milk in PBS-T 
After electrophoresis, SDS – gels were separated from the glass plates 
and marked at one end. The PVDF membrane (Immobilon-P, 0.45 µm, 
Millipore, Billerica, MA) and filterplates (blotting paper 703, VWR, 
Darmstadt, Germany) were cut to fit the size of the gel. The PVDF 
membrane was shaken with methanol (1 min.) and equilibrated together 
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with the gel in blotting buffer (5 min.). Finally the sandwich was assembled 
by putting membrane and gel between 3 buffer soaked filter papers at 
each side. The proteins were transferred onto the membrane at a constant 
voltage (15 V, 1 h) using the Semi-Phor blotting apparatus (Hoefer 
Scientific Instruments, San Francisco, CA). 
To prevent antibodies from unspecific binding to the membrane, it was 
shaken with blocking solution (1 h, 4ºC). Incubation with the primary 
mouse anti-human EBI3 antibody were carried out in a 50 ml falcon tube 
(Sarstedt, Nümbrecht, Germany) with a minimum of 4 ml antibody solution 
diluted in blocking solution (7 rpm, overnight, 4ºC). After washing (3x 10 
min.) membranes were incubated with the secondary HRP conjugated 
anti-mouse-Ig antibody dilution (1:10000 in blocking buffer) in 50 ml falcon 
tube (7 rpm, overnight, 4ºC). The membranes were washed 3 times for 10 
min. 
Enhanced chemiluminescence (ECL) was used for the detection of 
proteins. Therefore membranes were incubated with ECL solution (20 ml 1 
M Tris pH 8.8, 500 µl p-coumaric acid 340 mg in 26 ml DMSO, 1 ml 
Luminol 2.26 g in 51 ml DMSO, 180 ml aqua dest.) mixed with 3 µl/ml 3% 
hydrogen peroxide for 1 min., placed between two plastic overhead 
sheets, covered with a Kodak XAR film (Sigma-Aldrich, St. Louise, MO) 
and placed into a film cassette. After exposure from 1 s up to 1 h specific 
bands were visible on the film where light had been emitted during HRP 
enzyme activity after developing the film in a developing machine. 
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3.21 Quantification of cytokines via LUMINEX100  
The Flourokine MAP system, using LUMINEX xMAP technology (R&D 
Systems Inc.,  Minneapolis,  MN),  provides  a  tool  to  simultaneously  
measure  multiple cytokines  in  a  single  sample.  Analyte-specific 
antibodies are pre-coated onto colour-coded beads.  Standards  and  
samples  are  pipetted  into  the  wells  and analytes  of  interest  are  
bound  by  the  immobilized  antibodies.  After washing away any unbound 
substances, labelled antibodies specific to the analytes of interest are 
added.  Following  a  wash  to  remove  any  unbound  labelled antibodies,  
the  beads  are  resuspended  in  buffer  and  read  using  the LUMINEX100 
analyser. Cell culture - supernatants remaining from various experiments 
(DC incubated with or without human recombinant IL-35) were measured 
via the Luminex100 System (R&D Systems Inc., Minneapolis, MN) for their 
content of IL-10, IL-6, IL-1β, IL-12 p40, IL-12p70 and TNFα. 
3.22  Cell culture of tumor cell lines 
Cells of the Hela Ohio, A431, Jurkat, Daudi and Otma cell lines were 
cultured in RPMI1640 (Gibco Ltd., Paisley, Scotland) supplemented with 
10% characterized FCS (Sigma-Aldrich), 2 mM L-glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin (Sigma-Aldrich). The SCC cell line was 
cultured in DMEM (Gibco Ltd., Paisley, Scotland) supplemented with 10% 
characterized FCS (Sigma-Aldrich), 2 mM L-glutamine, 100 U/ml penicillin, 
100 µg/ml streptomycin (Sigma-Aldrich), non-essential amino acids, 5 
µg/ml Insulin (Sigma Aldrich) and 10 µg/ml Transferrin (Sigma Aldrich). 
Cells were cultured at 37°C with 5% CO2. 
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3.23  Buffers and media  
RPMI medium: Gibco Ltd., Paisley, Scotland 
Heparin medium: 
500ml RPMI 1640 medium supplemented with 1% glutamine and 2.5 ml 
antibiotic solution, i.e. (prepared penicillin/streptomycin mixture stored at –
20°C). Add 1 ml heparin (EBEWE Pharma, Unterach, Au stria) of the stock 
solution. 
DMEM medium: Gibco Ltd., Paisley, Scotland 
Freezing medium: 
RPMI 1640 supplemented with 25% FCS and 10% DMSO (Sigma) 
MACS-buffer (stored at 0°C): 
1000 ml 1x PBS def. + 25 ml HSA (stock: 20%, Centeon, Vienna) + 10 ml 
EDTA (stock: 0.5 M); sterile filtered  
10x PBS stock solution: 
5.8 g KH2PO4 16.6 g Na2HPO4 2H2O 72 g NaCl Solubilise the salts in 
aquabidest (=ddH2O), fill up to 10 litres and adjust pH to 7.2 
PBS/BSA stock solution (20%): 
100 g BSA 10 g NaN3 dissolved in 500 ml PBS buffer. For the PBS/BSA 
wash buffer, prepare a 1:20 dilution with PBS buffer. 
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4 RESULTS 
4.1 Human IL-35 fusionprotein can be detected by an anti-EBI3 mAb  
We have described recently that human rhinovirus (HRV) activated DCs, 
named R-DCs, induce suppressor function in T cells and the production of 
IL-35 by these cells. The supernatant of this R-DC/T cell co-culture 
reduces the proliferation of T cells that were activated via DCs (43). To 
test the function of IL-35 alone we investigated in a human IL-35 
fusionprotein. It carries an Fc fragment, named IL-35:Fc. First of all we 
determined if an anti-EBI3 mAb recognizes this protein in a western blot to 
prove its IL-35 identity. Therefore samples with 0.1 µg or 1 µg of IL-35:Fc 
were generated and analysed with the anti-EBI3 mAb or with anti-VIAP 
mAb, a IgG1 isotype control, as negative control. 
As shown in Figure 6 the human IL-35 was detected with the anti-EBI3 
mAb. Therefore it can be assumed that the protein concerns IL-35. 
 
 
Figure 6: Anti-EBI3 mAb detects IL-35:Fc  
Samples of 0.1 µg or 1 µg IL-35:Fc (right) were generated for SDS-PAGE. Specific 
signals for EBI3 were detected by western blot analysis. 
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4.2 Human recombinant IL-35 suppresses peripheral blood T cell 
proliferation induced by dendritic cells 
Because of our recent findings, we investigated in the effects of the human 
recombinant IL-35 on T cell proliferation. Therefore we co-cultured 
peripheral blood T cells with monocyte derived DCs and graded amounts 
of IL-35 for 5 to 6 days. The DCs were either immature or LPS activated 
(mDCs). We observed a suppression of T cell proliferation induced by 
immature as well as mature DCs that is most effective at a concentration 
of 1 ng/ml IL-35. The titration curve is depicted in Figure 7. 
 
 
Figure 7: IL-35 suppresses T cell proliferation most effective at a concentration of 1 ng/ml 
DCs (1x104 cells) were co-cultured with peripheral blood T cells (1 x 105) and graded 
amounts of human IL-35 from 100 ng/ml to 0.01 pg/ml for 5 days. Black filled triangles 
show immature DCs; white triangles show LPS activated DCs (24h). Proliferation of T 
cells was monitored on day 5 culture by adding [methyl-3H]TdR  followed by measuring  
[methyl-3H]TdR incorporation 18h  later. The results of one representative experiment of 
3 independent experiments are shown. Mean values of triplicate determinations ± 
standard deviation are shown.  
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4.3 The suppression of T cell proliferation through IL-35 is 
comparable to the supernatant of a R-DC/T cell co-culture 
We further investigated in the suppressive function of IL-35. Therefore we 
compared the supernatant of a R-DC/T cell co-culture with the human 
recombinant IL-35. To generate R-DCs monocyte derived dendritic cells 
were first incubated with HRV14 for 48 hours. Then R-DCs or untreated 
DCs were co-cultured with T cells in a 1:5 to 1:10 ratio for 1 day. The 
supernatants of these co-cultures were harvested and tested for their 
inhibitory effect in a MLR. To test whether IL-35 alone also has suppressor 
function, human IL-35 was added to the MLR. Therefore 1 x 104 DCs were 
mixed with 1 x 105 T cells and the supernatant of the DC/T cell co-culture 
or the R-DC/T cell co-culture (at a volume of 100 µl) or 1 ng/ml human IL-
35 was added. We tested isolated peripheral blood T cells and naive T 
cells from cord blood for their proliferation capacity after DC stimulation. 
Human IL-35 suppresses proliferation of peripheral blood T cells after DC 
activation almost as efficient as the supernatant of a R-DC/T cell co-
culture, which was previously described (Fig. 8A). In contrast, naive T cell 
proliferation was not inhibited by IL-35 or the supernatant of R-DC/T cell 
co-culture (Fig. 8B). The supernatant of a DC/T cell co-culture has no 
effect on T cell proliferation. The same effect of inhibition by IL-35 and the 
R-DC/T cell co-culture supernatant can be shown when T cells were 
activated with LPS treated mature DCs (mDCs) as depicted in Figure 8C. 
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Figure 8: IL-35 inhibits DC dependent T cell proliferation 
DCs (1x104 cells) were co-cultured with A) peripheral blood T cells or B) naive T cells of 
cord blood (1x105 cells) and the supernatants of DC/ T cell, R-DC/T cell co-culture or 1 
ng/ml of human IL-35 for 5 days. C) DCs were activated for 24h with LPS and then co-
cultured with peripheral blood T cells for 5 days. Proliferation of T cells was monitored on 
day 5 culture by adding [methyl-3H]TdR  followed by measuring  [methyl-3H]TdR 
incorporation 18h  later. The results of one representative experiment of 3 independent 
experiments are shown. Mean values of triplicate determinations ± standard deviation are 
shown. 
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4.4 Human recombinant IL-35 does not affect T cell proliferation in 
absence of APCs 
To determine if T cell proliferation induced by an APC-free or DC-free, 
alternative stimulation can also be inhibited through human IL-35, we used 
different monoclonal antibodies for T cell activation. TCR signalling is 
initiated through the binding of the CD3 mAb (OKT3) to the ζ-chain of the 
CD3 molecule expressed on mature T cells. T cells deliver signal 1 by 
binding of OKT3 and get activated. Signal 2, induced by co-stimulation, is 
provided by the binding of anti-CD28 and anti-CD63 mAbs. The co-
stimulatory molecules CD28 and CD63 are expressed on T cells and 
induce a stronger T cell activation signal when they interact with their 
ligands on APCs. Human peripheral T cells were activated with plate-
bound mAbs against CD3, CD3 combined with CD28 and CD3 in 
combination with CD63. Different concentrations of human IL-35 were 
added and the cells were cultured for 3 days. 
As shown in Figure 9 human IL-35 does not affect T cell proliferation after 
anti-CD3, anti-CD3/CD28 or anti-CD3/CD63 stimulation. There was 
neither an increase nor a decrease in comparison to the untreated T cells. 
Even high doses of IL-35 did not reveal differences in T cell proliferation. 
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Figure 9: DC independent T cell proliferation cannot be suppressed by IL-35 
T cells were stimulated with plate-bound A) CD3, B) CD3/CD28 and C) CD3/CD63 mAb 
or mock stimulation for 3 days and cultured in the presence of 0.1, 1 and 10 ng/ml of 
human IL-35. Proliferation of T cells was monitored  on  day  5  of  culture  by  adding  
[methyl-3H]TdR  followed  by measuring [methyl-3H]TdR incorporation 18 h later. The 
results of one representative experiment of 3 independent experiments are shown.  Mean 
values of triplicate determinations ± standard deviation are shown.  
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4.5 DCs pretreated with human recombinant IL-35 have a reduced T 
cell stimulatory capacity 
As shown before T cell proliferation can be inhibited by human IL-35, 
when DCs serve as stimulators. But in a DC-free environment, activated 
through binding of anti-CD3, anti-CD3/CD28 and anti-CD3/CD63 mAbs, T 
cells treated with IL-35 proliferate the same way as the untreated cells do. 
So we investigated whether IL-35 does affect DCs or T cells. We tested 
the direct effect of IL-35 on DCs. Therefore monocytes were cultivated 
with IL-4 and GM-CSF for three days, not yet reaching the DC status. We 
added IL-35 or IL-10, for comparison, and continued culturing them for 
another three days. After these six days we got DCs, further termed IL-35-
DCs or IL-10-DCs. We also generated untreated DCs, which serve as 
control. On day 6 the immature DCs were activated with LPS to get 
mature DCs (Fig. 9). After 24 hours the cells were harvested and 
supernatants were collected. We performed a MLR with these DCs as 
stimulators and analysed the cells for their surface marker profile. 
Cytokines typical for DCs were measured via LUMINEX100. The workflow 
of this DC generation is depicted in Figure 10. 
 
Figure 10: Scheme of IL-35-DCs generation 
Monocytes were cultivated with IL-4 and GM-CSF for 3 days, IL-35 or IL-10 was added. 
After 3 days DCs were activated with LPS for 24 hours. 
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4.5.1 IL-35-DCs have a reduced capacity to activate T cells 
We investigated whether these IL-35 pretreated DCs (IL-35-DCs) have 
reduced T cell stimulatory capacity. To compare the effect with a known 
DC suppressor cytokine, we also generated IL-10 pretreated DCs (IL-10-
DCs). IL-10 is described to inhibit DCs by reducing IL-12 and IFNγ release 
(2).  
DCs, IL-35-DCs and IL-10-DCs, either immature or LPS activated, were 
co-cultured with T cells for 5 days. We observed that DCs treated with IL-
35 have a reduced capacity to stimulate T cells. Immature IL-35-DCs show 
a similar suppression of T cell proliferation as IL-10 treated cells (Fig.11A). 
Compared to the co-culture of untreated DCs and T cells with addition of 
recombinant IL-35 the T cell stimulatory capacity of the IL-35-DCs is even 
more reduced (Fig. 8). When IL-35-DCs were activated with LPS they lose 
their ability to inhibit T cell proliferation. This effect cannot be compared 
with matured IL-10-DCs, because they maintain their inhibitory character 
(Fig. 11B). 
 
Figure 11: Immature IL-35-DCs inhibit T cell proliferation nearly as efficient as IL-10 
treated DCs 
DCs, IL-35-DCs or IL-10-DCs (1 x 104 cells), immature (A) or LPS-activated (B) were co-
cultured with peripheral blood T cells (1 x 105 cells) for 5 days. Proliferation of T cells was 
monitored on day 5 culture by adding [methyl-3H]TdR  followed by measuring  [methyl-
3H]TdR incorporation 18 h  later. The results of one representative experiment of 6 
independent experiments are shown. Mean values of triplicate determinations ± standard 
deviation are shown. 
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4.5.2 Cell surface marker profile of IL-35-DCs 
Typical surface molecules, such as CD83 or MHC II, expressed on DCs 
get up-regulated when they are activated. In the presence of inhibitory 
factors like IL-10 the expression level of these DC markers decreases in 
immature cells (2). Therefore we analysed the expression levels of CD1a, 
CD14, CD40, CD80, CD83, CD86, MHC I, MHC II, B7-H1, B7-H3 and 
Siglec-1 on DCs, IL-35-DCs or IL-10-DCs. CD1a and CD14 served as 
controls for the verification that monocytes changed to DCs, because 
CD1a is expressed on DCs and CD14 is expressed on monocytes and its 
expression decreases on DCs. The surface markers CD40, CD80, CD83, 
CD86, MHC I, MHC II, B7-H1, B7-H3 and Siglec-1 are higher expressed 
when DCs get mature. IL-10 decreases the expression of co-stimulatory 
molecules, like CD80 and CD86, and MHC on DCs (2). The expression 
levels were measured by flow cytometry. 
As shown in Figure 12A, the expression of all tested surface markers 
remained unchanged when DCs were incubated with IL-35. LPS activation 
leads to a general up-regulation of the DC markers. Comparison with LPS-
activated IL-35-DCs shows that the markers CD83, CD40, CD80, CD86, 
MHC I, MHC II, B7-H1, Siglec-1 and B7-H3 are expressed at the same 
level. CD14 expression was unaffected at the majority of the FACS 
staining (Fig. 12B). In IL-10 pretreated DCs compared to untreated DCs 
the expression levels of the surface markers remain mostly unaffected 
(Fig. 12C). When IL-10-DCs were activated with LPS the cells persist 
immature, because the expression of the surface molecules in comparison 
to mature DCs is diminished (Fig. 12D). It seems that maturation cannot 
be achieved when DCs were cultured with IL-10 during their development.  
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Figure 12: Surface marker profile of DCs compared with IL-35-DCs 
Immature DCs and IL-35-DCs (A), DCs and IL-35-DCs stimulated with LPS for 24h (B),  
immature DCs and IL-10-DCs (C), DCs and IL-10-DCs stimulated with LPS for 24h (D) 
were stained with the mAbs against CD1a, CD14, CD83, CD40, CD80, CD86, MHC I, 
MHC II, B7-H1, Siglec-1 and B7-H3 and analysed by FACS. Black dotted line: Isotype 
control; grey filled histogram: DCs or mDCs, black line: DCs/mDCs treated with IL-35 or 
IL-10. FACS histogram plots of 1 representative experiment out of 3 are shown. 
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4.5.3 Cytokine profile of IL-35 treated DCs 
We further analysed the effect of IL-35 on cytokine secretion by DCs. After 
addition of IL-35 or IL-10 to DCs and activation with LPS, we harvested 
the supernatants and determined the levels of secreted cytokines. We 
measured IL-10, IL-1β, IL-6, IFNγ, TNFα and IL-12p40, one subunit of the 
IL-12 cytokine. For IL-10-DCs we expected a decreased IL-12p40, IL-6 
and TNFα production compared to untreated DCs. We were interested if 
IL-35-DCs also have a diminished pro-inflammatory cytokine secretion. 
Therefore we collected the supernatants of DCs, IL-35-DCs and IL-10-
DCs, immature and LPS activated, and analysed them via LUMINEX100. 
There is no release of cytokines detected in the supernatants of immature 
DCs, because the release starts when DCs were activated. Pretreatment 
of DCs with IL-35 or IL-10 does not affect the secretion. Only IL-10 is 
detectable in the supernatant IL-10-DCs due to the fact that IL-10 was 
added during IL-10-DCs generation. The same effect occurs after LPS 
activation. Figure 13 shows that IL-10 release by mature DCs is reduced 
after IL-35 treatment and also IL-12p40 is suppressed although to a lesser 
degree. But the secretion of IL-6 and TNFα by LPS activated IL-35-DCs 
increased slightly, whereas the supernatants of IL-10-DCs show a down-
regulation of these cytokines compared to untreated DCs. 
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Figure 13: Cytokine profile of the supernatants of DCs, IL-35-DCs and IL-10-DCs 
The supernatants of the DCs were harvested after IL-35 or IL-10 addition and LPS 
activation. The cytokines IL-10, IL-1β, IL-6, TNFα and IL-12p40 were measured via 
LUMINEX100. The results of one representative experiment of 3 independent experiments 
are shown. 
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4.6 Human IL-35 fusionprotein binds to DCs but not to peripheral 
blood T cells 
Because of the assumption that IL-35 acts on DCs by inhibiting their T cell 
stimulatory capacity, we were interested if IL-35 can also bind to DCs 
and/or T cells. Therefore we used a human IL-35 fusionprotein fused to a 
Fc fragment, termed IL-35:Fc. We were able to detect its binding via a 
secondary mAb that binds to the Fc part of the fusionprotein. We blocked 
the Fcγ receptors of the cells with a mouse IgG mAb, and then incubated 
them with IL-35:Fc. For detection of cells that bind IL-35 a secondary 
phycoerythrin-conjugated F(ab)2 fragment goat-anti human, Fcγ specific, 
IgG was added and the cells were analysed via FACS. Human 
immunoglobulin (IgG), termed Beriglobin, served as negative control. A 
CTLA-4 fusionprotein fused to the Fc fragment also served as a control, 
because its receptors, CD80 and CD86, are expressed on DCs (118). We 
analysed the binding ability of IL-35:Fc to monocytes, DCs, mature DCs 
(mDCs) activated with LPS and peripheral blood T cells via flow cytometry. 
Results presented in Figure 14 show that IL-35 binds to DCs to the same 
extent as CTLA-4 does. The expression of the unknown IL-35 receptor 
seems to increase on DCs when they were activated with LPS. These 
findings were observed in two experiments out of five, so clearly more 
tests have to be performed. Monocytes neither bind CTLA-4 nor IL-35.  A 
binding of IL-35 to T cells was also not detected. The ability of the IL-35:Fc 
to bind DCs goes in accordance with the found reduction of the T cell 
stimulatory capacity of DCs.  
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Figure 14: Binding analysis of IL-35:Fc 
Monocytes were incubated with IL-4 and GM-CSF for 6 days to obtain DCs, T cells were 
purified from blood. The cells were blocked with human IgG, VIAP, and incubated with 
CTLA-4:Fc (left) or IL-35:Fc (right). Beriglobin serves as negative control (grey 
histogram). The black line shows CTLA-4 or IL-35. The binding was detected with a 
phycoerythrin-conjugated F(ab)2 fragment goat-anti human, Fcγ specific, IgG via FACS. 
The results of one experiment out of 2 positive ones from 5 independent experiments are 
shown. 
 
4.7 Human IL-35:Fc binds to HeLa Ohio cells but not to other cell 
lines 
Because of the binding ability of IL-35:Fc to DCs, we wondered how 
specific this effect would be. Therefore we tested whether the IL-35:Fc can 
bind other cell types. We analysed epithelial (HeLa Ohio, A431 and 
squamous cell carcinomas (SCC), and hematopoietic (Jurkat and Otma) 
cell lines. The binding analysis shows that IL-35:Fc binds to HeLa Ohio 
cells but not to the other tested cell lines, as shown in Figure 15. 
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Figure 15: Binding analysis of IL-35:Fc fusionprotein to the utilized cell lines 
The cells were blocked with human IgG, VIAP, and incubated with IL-35:Fc. Beriglobin 
served as negative control (grey histogram). The black line shows IL-35. The binding was 
detected with a phycoerythrin-conjugated F(ab)2 fragment goat-anti human, Fcγ specific, 
IgG via FACS. 
 
4.8 Human recombinant IL-35 suppresses cell growth of the tumor 
cell line HeLa Ohio 
HeLa was the first human epithelial cancer cell line established in long-
term culture. It was derived from an adenocarcinoma of the cervix in 1951 
from cancer cells (119). The cells have a hypertriploid chromosome 
number, specific numerical deviations and 20 clonally abnormal 
chromosomes (119).  The genome of HeLa cells is characterized by 
multiple copies of the human papilloma virus type 18 (HPV18) integrated 
at specific sites (120). HeLa cells are adherent cells and sustain contact 
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inhibition in vitro. The HeLa Ohio cells are derivative of the parent HeLa 
line. 
To examine if the binding ability of IL-35 to HeLa Ohio cells goes in 
accordance to its inhibitory capacity we were interested if IL-35 has the 
capacity to suppress the cell growth of tumor cell lines. First we added 
human IL-35 to the HeLa Ohio cell line and measured their proliferation 
rate via thymidine incorporation. 
 We observed that IL-35 is able to inhibit the proliferation of HeLa Ohio 
cells (Fig. 16).  
 
Figure 16: Cell growth inhibition of HeLa Ohio cells by IL-35  
1 x 105 HeLa Ohio cells were cultured for 24 h with 10 ng/ml or 1 ng/ml human IL-35. 
Proliferation of HeLa Ohio cells was monitored by adding [methyl-3H]TdR  followed by 
measuring  [methyl-3H]TdR incorporation 18h  later. The results of one representative 
experiment of 3 independent experiments are shown. Mean values of triplicate 
determinations ± standard deviation are shown. 
Because of this finding we were interested whether IL-35 is a common 
tumor suppressor or this effect is HeLa specific. We tested the cell number 
of HeLa cells, the time point and the concentration of IL-35 to get an 
efficient tumor cell growth inhibition. We used 2.5 x 104, 5 x 104 and 7.5 x 
104 cells and let them grow for 24, 48 and 72 hours. Titrated IL-35 from 1 
µg/ml to 0.1 ng/ml was added to each approach. After 24, 48 or 72 hours 
we added H3 thymidine and harvested the cells 18 hours later. Figure 17 
shows the 48 hours time point with 5 x 104 HeLa Ohio cells. For further 
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experiments we decided to use 5 x 104 cells of each cell line and 10 ng/ml 
and/or 1 ng/ml human IL-35.  
 
 
Figure 17: Titration of IL-35 for cell growth inhibition in HeLa Ohio cells 
5 x 104 HeLa Ohio cells were co-cultured with 1 µg/ml to 0.1 ng/ml human IL-35 for 48h. 
Proliferation of HeLa Ohio cells was monitored by adding [methyl-3H]TdR  followed by 
measuring  [methyl-3H]TdR incorporation 18h  later. The results of one representative 
experiment of 3 independent experiments are shown. Mean values of triplicate 
determinations ± standard deviation are shown. 
 
4.8.1 Other epithelial cell lines show no suppressed proliferation 
after addition of IL-35 
Because of the suppressive effect of IL-35 on HeLa Ohio cells, we were 
interested if this cytokine is also able to inhibit the proliferation of other 
epithelial cell lines. We tested different squamous cell carcinomas (SCC) 
from the tongue, termed SCC4 and SCC9, and an epithelial cell line of the 
skin (A431).  
5 x 104 cells of each cell line were cultured with 10 ng/ml or 1 ng/ml for 48 
hours. Human IL-35 does not affect cell growth of these cells (Fig. 18).  
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Figure 18: IL-35 does not suppress the proliferation of other epithelial tumor cell 
lines 
5x104 cells of the cell lines SCC4, SCC9 and A431 were co-cultured with 10ng/ml or 
1ng/ml human IL-35 for 48h. Proliferation of the cells was monitored by adding [methyl-
3H]TdR  followed by measuring  [methyl-3H]TdR incorporation 18h  later. The results of 
one representative experiment of 3 independent experiments are shown. Mean values of 
triplicate determinations ± standard deviation are shown. 
 
4.8.2 IL-35 does not suppress cell growth of hematopoietic cell lines 
To determine if IL-35 has an effect on hematopoietic cell lines we tested 
three different cell lines. Jurkat cells, derived from human T cell 
leukaemia, Daudi cells, derived from Burkitts lymphoma and transformed 
with EBV, and Otma cells, EBV-transformed B cells, were cultivated with 
10 ng/ml or 1 ng/ml human recombinant IL-35 for 2 days. The proliferation 
of all three hematopoietic cell lines used cannot be suppressed with 
human IL-35 (Fig. 19). 
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Figure 19: IL-35 does not suppress the proliferation of various hematopoietic cell 
lines 
5 x 104 cells of Otma, Daudi and Jurkat were co-cultured with 10ng/ml or 1ng/ml human 
IL-35 for 48h. Proliferation of the cells was monitored by adding [methyl-3H]TdR  followed 
by measuring  [methyl-3H]TdR incorporation 18h  later. The results of one representative 
experiment of 3 independent experiments are shown. Mean values of triplicate 
determinations ± standard deviation are shown. 
 
4.9 EBI3 is up-regulated on T cells co-cultured with human 
rhinovirus or IFNα treated DCs 
We recently demonstrated that IL-35 is produced by regulatory T cells 
induced by human rhinovirus (HRV14) activated DCs (R-DCs). We could 
also show that EBI3, a subunit of IL-35, is up-regulated in T cells co-
cultured with these R-DCs (43). Because of these findings we were 
interested if EBI3 is also up-regulated in T cells when they were co-
cultured with other types of DCs. Therefore we stimulated monocyte 
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derived DCs for 3 days with HRV14, Lipopolysaccharide (LPS), Zymosan 
(ZYM), IFNα and poly-IC RNA. The differently activated DCs and, as 
control, immature DCs were co-cultured with T cells for 1 day. The cells 
were harvested and stained intracellulary for p35 and EBI3. The staining 
was analysed via FACS with a special attention on the T cells. 
Anti-S100-A4 mAb, a calcium-binding protein, and anti-Mxa mAb, an 
IFNα/β inducible protein, served as controls. The VIAP antibody serves as 
isotype control.  
As depicted in Figure 20 all T cells co-cultured with different types of DCs 
show S100-A4 expression. P35, a subunit of IL-35 and IL-12, is described 
to be constitutively expressed in all T cells, which is the case, and is up-
regulated in T cells co-cultured with virus treated DCs (R-DCs) and in T 
cells co-cultured with IFNα treated DCs. EBI3 is highly expressed on the 
R-DC treated T cells and the IFNα treated T cells. In all other types of 
activated T cells EBI3, which serves as a subunit for IL-35 and IL-27, is 
only expressed at very low levels. The positive control for virus infected 
and also for IFNα treated cells, Mxa, is highly expressed in those T cells 
as well. 
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Figure 20: EBI3 and p35 are up-regulated in T cells co-cultured with R-DCs or IFNα 
treated DCs 
Immature DCs and DCs activated with HRV14, LPS, Zymosan, IFNα and poly IC (from 
top)  for 3 days were co-cultured with T cells from a different donor for 1 day and then 
stained intracellulary with mAbs against S100, p35, EBI3 and Mxa (from left) and 
analysed by FACS. Cells were gated on T cells. Grey histogram: Isotype control; black 
line: specific mAb.  FACS histogram plots of 1 representative experiment out of 3 are 
shown. 
 
4.10 T cells co-cultured with R-DCs show a diminished CD2 
expression 
In the FACS analysis of differently activated DCs in combination with T 
cells we were also interested in various surface markers of T cells. We 
observed no effect at the expression levels of the most markers. But when 
T cells were co-cultured with R-DCs we observed that CD2 expression 
declines compared to a DC/T cell co-culture. CD2 is a 50-55 kDa 
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glycoprotein and is expressed on T cells, like CD3, and is also expressed 
on NK cells. It binds to CD58, which is expressed on APCs. CD2 forms 
loose association with the TCR complex and the CD2-CD58 interaction 
initiates T cell/ APC contact. As described before we co-cultured DCs or 
R-DCs with T cells for 24 hours and then stained all cells on the surface 
with an anti-CD2 mAb. The staining was analysed via FACS with a special 
attention on the T cells. 
We observed that the expression level of CD2 is down-regulated on T 
cells when they were co-cultured with R-DCs but not with immature DCs 
(Fig. 21). 
 
 
Figure 21: CD2 expression is down-regulated in T cells co-cultured with R-DCs 
DCs and R-DCs were co-cultured with T cells for 1 day and then stained for CD2. The 
black line shows the isotype control and the red line shows the CD2 expression. MFI 
accords to the MFI of CD2 minus the isotype control. FACS histogram plots of 1 
representative experiment out of 3 are shown. 
 
4.11 CD2-/low/CD3+ T cell subpopulation in different donors 
We found out that, after the stimulation with R-DCs, the T cell population 
shows a decrease in the CD2 expression. T cells always express CD3 on 
their surface. Such a subpopulation of CD2-/low/CD3+ T cells was first 
identified in fetal human T cells of the spleen and thymus in 1988. These 
cells proliferate well and produce IL-2 when treated with anti-CD3 mAbs 
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(113,115). We were interested in which amounts these CD2-/low/CD3+ T 
cells are represented in different donors. Therefore we isolated the 
mononuclear cells from fresh blood from various donors and analysed 
their CD2 and CD3 expression via FACS. The number of this 
subpopulation is low and varies from donor to donor (MV 0.6% +/- 0.5 SD 
of PBMNCs). The percentage of CD2-/low cells in CD3+ T cells is about MV 
1.6% +/- 1.2 SD.  CD2-/low/CD3+ T cells are represented in the range of 
0.5% to 3.9%. The stainings of PBMNCs gated on lymphocytes of two 
representative donors are depicted in Figure 22 and the percentages of 
CD2-/low T cells in PBMNCs or T cells are shown in Table 1. 
 
Figure 22: Surface expression of CD2 and CD3 in mononuclear cells 
PBMNCs were isolated from fresh blood and stained with FITC labelled anti-CD3 and 
with PE labelled anti-CD2 mAbs (VIAP served as isotype control). FACS dot plots of 2 
representative donors out of 7 are shown. 
 
 
Table 1: Percentage of CD2-/low T cells  
Percentage of CD2-/low T cells out of PBMNCs (upper row) or CD3+ T cells (lower row) 
are shown. 
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5 DISCUSSION 
 
IL-35 is the most recently described cytokine of the IL-12 family (37,38) 
(39). It is known to have anti-inflammatory activity in the mouse system, 
because it is produced by CD4+CD25+FoxP3+ T regs and the inhibition of 
Th17 polarization. In mice IL-35 contributes to the suppressive function of 
T regs (37,39). Controversially, in humans IL-35 is not constitutively 
expressed in natural T regs and it does not contribute to the suppressive 
function of FoxP3 induced T regs (41,42). Our recent findings demonstrate 
that IL-35 producing T regs can be induced by interaction of DCs with T 
cells via B7-H1 and Sialoadhesin, which are up-regulated when DCs get in 
contact with human rhinovirus (43). What we know about IL-35 is that it is 
produced by T regs, but it is not clear which role IL-35 plays in the immune 
response, how it influences the inhibition of T cell proliferation and which 
cell type interacts with this cytokine.  
We have previously shown that the supernatant of a R-DC/T cell co-
culture, containing IL-35, inhibits T cell proliferation (43). We wanted to 
find out if a human recombinant IL-35 alone inhibits T cell proliferation as 
efficient. We observed that T cells get activated via allogeneic DCs show 
reduced proliferation in the presence of IL-35. This reduction is 
comparable with the inhibition capacity of the supernatant of the R-DC/ T 
cell co-culture. The same effect was obtained with LPS activated DCs, 
although mature DCs have an increased competence to stimulate T cells. 
IL-35 alone is able to suppress the proliferation of T cells. But without DCs 
as stimuli, when T cells were activated alternatively with anti-CD3, anti-
CD3/CD28 and anti-CD3/CD63 mAbs, IL-35 was no longer capable to 
reduce the growth of T cells. It seems that IL-35 only practices its 
inhibitory function on T cell stimulation in presence of DCs. Naive T cells 
from cord blood cannot be inhibited by IL-35, neither through DC activation 
nor through TCR and co-stimulatory molecule stimulation. IL-35 is not a 
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typical cytokine of the IL-12 family, because it is produced by Tregs not by 
APCs. In this study we found out that IL-35 is a inhibitory cytokine which 
acts on DCs. This differs from all other described IL-12 family members, 
which affect T cells. 
So DCs play an important role in IL-35 function. To determine how IL-35 
influences DCs we performed an assay where they were directly affected 
by IL-35 as it was added in the development phase of DCs from 
monocytes. IL-10 served as a comparable cytokine because of its 
described suppressor functions. Pretreated DCs, either through IL-35 (IL-
35-DCs) or through IL-10 (IL-10-DCs) also have a diminished capacity to 
induce T cell proliferation. The quantity of the suppressive effect of IL-10-
DCs and IL-35-DCs is comparable. This effect was not detectable when 
the DCs were matured with LPS. So IL-35 reduces the T cell stimulatory 
capacity of DCs in their developmental phase. But LPS seems to abrogate 
this effect and activated IL-35-DCs are able to induce T cell proliferation 
as efficient as mature DCs. 
The development of DCs from monocytes seems to be unaffected by IL-
35, because the cells look like DCs after the 6 day co-culture. After 6 days 
the cells, co-cultured without cytokines or with IL-35 or IL-10, display 
extensions and loose their round shape. Also the surface markers 
correspond to DCs, because IL-35-DCs express CD1a but no CD14 as 
untreated DCs do. IL-10-DCs show no difference in their surface marker 
expression compared to untreated DCs as previously described (121). The 
surface marker profile of IL-35-DCs behaves similar, because they remain 
expressed on the same level as on immature DCs. After LPS addition the 
surface markers are up-regulated. In presence of IL-10 the anticipated 
increase of the surface molecule expression is missed. As already 
described we also observed that IL-10-DCs cannot be matured through 
LPS activation (121). In contrast, the maturation of DCs is not affected by 
IL-35, because the expression of CD83, CD40, CD 80, CD86, MHC I, 
MHC II, B7-H1, B7-H3 and Siglec-1 remains at the same level as in 
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untreated mature DCs. This effect is not equivalent with IL-10-DCs and 
serves as a possible explanation why mature IL-35-DCs induce T cell 
proliferation as efficient as mature DCs. 
For the detection of typical DC cytokines the cells have to be activated, 
because cytokine secretion increases with maturation. All measured 
cytokines are not detectable in the supernatants of immature DCs, IL-35-
DCs and IL-10-DCs. Therefore no difference in their cytokine release can 
be observed. The supernatant of immature IL-10-DCs contains IL-10, what 
could be explained by IL-10 pretreatment. But the possibility of IL-10 
induction has to be tested by performing more experiments. LPS strongly 
induces the release of pro-inflammatory cytokines, so IL-10, IL-1β, IL-6, IL-
12 and TNFα are up-regulated with maturation. Compared to untreated 
mature DCs, IL-35-DCs show a slight increase in IL-1β, IL-6 and TNFα 
secretion upon stimulation with LPS. This differentiates from LPS activated 
IL-10-DCs, because they suppress cytokine release of IL-6 and TNFα as 
well. But in case of IL-12p40 the supernatant of IL-35-DCs exhibits a slight 
down-regulation, whereas IL-10-DCs strongly diminish IL-12p40 detection. 
Interestingly, this inhibitory cytokine, IL-35, down-regulates IL-10 secretion 
in DCs. But this could explain why the suppressive effect of IL-35-DCs is 
missed in matured cells. It also designates a T cell response that keeps off 
Th1 and the up-regulation of IL-6 could be an indication for Th17, because 
IL-6 in combination with TGFβ are essential for Th17 cell differentiation 
(80).  
It was described that the inhibition of cytokines by IL-10 is not responsible 
for the impaired stimulatory capacity of DCs. But the alteration of surface 
molecule expression after IL-10 treatment and the modified DC – T cell 
contact plays a crucial role (121).  The mechanism for the reduction of the 
T cell stimulatory capacity of IL-35-DCs is not yet known. It is not 
explainable through changes in their surface molecules expression and 
their cytokine profile. In LPS activated IL-35-DCs the suppressor function 
is lost, what could be explained through the slight up-regulation of pro-
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inflammatory cytokines and the decrease of IL-10, as a suppressor 
cytokine. To get more information about the mechanism more studies 
have to be performed. 
Today the receptor for IL-35 is not known. In binding assays we analysed 
if IL-35 is able to bind to various cell types. We observed that IL-35 
interacts with DCs and LPS activated DCs but not with T cells and 
monocytes. So it is possible that the receptor of IL-35 is only expressed on 
DCs. Collison and Vignali proposed that the receptor chains of other 
members of the IL-12 family build this receptor. The IL-12Rβ2 chain binds 
to the p35 subunit, which also exists in IL-12, and therefore it is a feasible 
candidate. IL-27, which carries EBI3 as well, requires both receptor 
subunits, gp130 and WSX-1, for signalling. It is possible that both chains 
are part of the IL-35 receptor or only one of them (11). Gp130 is also part 
of the IL-6 receptor and associates with other receptor components to 
generate different receptors (122). All of the three possible receptor chains 
are expressed in T cells and in DCs (123,124,125,126), but IL-12Rβ2 is 
not expressed on monocytes (127). Therefore none of these chains or 
only one of them may be involved in the IL-35 receptor formation. It is also 
possible that new, unknown subunits build this receptor alone or maybe 
with one or two chains of the proposed ones. Table 1 shows on which cell 
types IL-35 binds in our study and which receptor subunits are expressed 
on these cells. In Figure 23 the possible chains of the IL-35 receptor 
candidates are depicted. 
 
Table 2: Summary of IL-35 binding assays compared to the known receptor 
subunits of the described IL-35 subunits 
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Figure 23: Possible subunits for the IL-35 receptor (detail of Collison and Vignali, 
2008, Immunol Rev) 
We demonstrated that IL-35 is able to inhibit tumor cell growth of the HeLa 
Ohio cell line. Interestingly the capacity of IL-35 to suppress HeLa Ohio 
proliferation increases from 1 µg/ml to 1 ng/ml and then decelerates. So 
the amount of IL-35, which corresponds to cell growth inhibition, is very 
important. Other epithelial cell lines could not be suppressed by IL-35. 
Also the tested hematopoietic cell lines show no difference in their 
proliferation when IL-35 was added. The binding assays demonstrate that 
IL-35 only binds to HeLa Ohio cells but not to the other tested cell lines. 
So there is probably no cell growth inhibition in the other epithelial and 
hematopoietic cell lines because of the lack of specific receptors for the 
interaction with IL-35. To conclude these findings we can say that IL-35 
does not serve as a common tumor suppressor, because the inhibitory 
capacity seems to depend on cells that carry the receptor or not. 
IL-35 is produced by regulatory T cells induced by R-DCs. That was for 
example demonstrated by the up-regulation of EBI3 in T cells co-cultured 
with these R-DCs (43). Because of these facts we were interested if EBI3 
is also up-regulated in T cells co-cultured with differently activated DCs. 
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We found out that T cells co-cultivated with IFNα activated DCs also 
express EBI3 in a higher level, like T cells that were activated with R-DCs. 
All the other types of differently stimulated T cells show no influence in 
EBI3 expression. IFNα is produced in high levels when cells are in contact 
with virus. Viral components are detected by several receptors, such as 
TLR3, Mda-5 and Rig-I, what causes signal transduction for type I IFN 
production (128). When DCs are activated with HRV, IFNα is also induced. 
In combination with these facts the EBI3 up-regulation may be associated 
with viral infection. Mxa, an intracellular factor induced by type I IFNs, is 
expressed on T cells co-cultured with R-DCs and on T cells co-cultured 
with IFNα activated DCs (129). The flow cytometry results show that p35 is 
expressed in all types of differently stimulated T cells in low doses and 
gets more in cause of DCs plus HRV or DCs plus IFNα. IL-35, consistent 
of p35 and EBI3, is produced by R-DC induced regulatory T cells, what 
explains the up-regulation of the p35 and EBI3 expression compared to T 
cells co-cultured with untreated DCs. Maybe IL-35 is also a product of T 
cells that were activated with IFNα-DCs. 
The FACS analysis of different surface molecules on T cells that were co-
cultured with R-DCs or immature DCs suggests that the CD2 expression 
decreases when T cells were activated via R-DCs. So a population of 
CD2-/low T cells appears. CD2-/low/CD3+ T cells were first identified in fetal 
human T cells of the spleen and thymus in 1988 (113). We know that IL-35 
is produced by T regs that were induced by R-DCs, but the special type of 
these cells is not yet described. These R-DCs co-cultured T cells have a 
decreased CD2 expression. That combination raises the question if these 
CD2-/low/CD3+ T cells are possible IL-35 producers. So we wanted to know 
if we can detect such a subpopulation in the blood of healthy donors via 
flow cytometry. In mononuclear cells these CD2-/low/CD3+ T cells are not 
easy to detect. But we also observed that the number of this 
subpopulation varies from donor to donor without R-DC treatment. Maybe 
the frequency of this subpopulation in different donors correlates with 
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infectious diseases the persons currently have or had. But to answer these 
questions more studies have to be performed. 
To sum up our findings we can say that IL-35 produced by T regs acts on 
DCs and binds to them. IL-35 is also for the reduction of the T cell 
stimulatory capacity of DCs. The subpopulation of T regs which release IL-
35 is not yet known, but a possibility lies in the CD2-/low/CD3+ T cell 
population. Figure 24 demonstrates a hypothesis of the functional effects 
of IL-35. 
 
Figure 24: Summary 
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